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Abstract A considerable number of genes that code for
AU-rich mRNAs including cytokines, growth factors, tran-
scriptionalfactors,andcertainreceptorsareinvolvedinboth
chronic inﬂammation and cancer. Overexpression of these
genes is affected by aberrations or by prolonged activation
of several signaling pathways. AU-rich elements (ARE) are
important cis-acting short sequences in the 30UTR that
mediate recognition of an array of RNA-binding proteins
and affect mRNA stability and translation. This review
addresses the cellular and molecular mechanisms that are
common between inﬂammation and cancer and that also
govern ARE-mediated post-transcriptional control. The ﬁrst
part examines the role of the ARE-genes in inﬂammation
and cancer and sequence characteristics of AU-rich ele-
ments. The second part addresses the common signaling
pathways in inﬂammation and cancer that regulate the
ARE-mediated pathways and how their deregulations affect
ARE-gene regulation and disease outcome.
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Introduction
Cancer and chronic inﬂammatory conditions including
autoimmune diseases are among the leading causes of
morbidity. Knowledge about the signaling pathwaysthat are
common between inﬂammation and cancer can lead to
deeper insights into the underlying molecular mechanisms
of disease and improved therapeutic approaches. A large
bodyofliteraturesupportsthenotionthatcommonsignaling
pathways are deregulated in chronic inﬂammation and
cancer (Table 1). In normal cells or cells that are not
undergoing inﬂammatory response, many signaling path-
ways are dormant, but become transiently activated during
immune response and cellular growth. In chronic inﬂam-
mation and cancer, continued activation of these signaling
pathways are distinct features in the biology of these two
processes. These same signaling pathways also lead to
increased stabilization of a class of mRNAs contributing to
the increased expression of these gene products that are
involved in inﬂammation and cancer. Cancer, as a disease,
spans alterations in many biological processes and is thus
involved not only in oncogenesis but also in maintenance,
invasion, hypoxia/nutrient deprivation response, angiogen-
esis, and metastasis. Certain genes of pro-inﬂammatory
nature contribute to one or more of these processes (Fig. 1).
Several key proteins that share common functions in
inﬂammation and cancer process are coded by AU-rich
mRNAs (Table 2). The AU-rich mRNAs are a class of
mRNAs that bear AU-rich elements (ARE) in their 30
untranslated regions (30UTR). Estimated now to be in the
vicinity of 10–15% of all transcripts [1], the ARE-mRNAs
comprise a functionally diverse group including inﬂam-
matory and immune response, transcription, cellular
proliferation, RNA metabolism, development, and signal-
ing [2]. This functional enrichment of ARE-genes
correlates with the rapid mRNA decay patterns, particu-
larly with those involved in transcription and signaling [3].
The mRNA stability is a product of not only the cis-acting
sequences such as the ARE but also transacting factors,
e.g., RNA-binding proteins, that bind directly or indirectly
to the cis-acting elements and promote the deadenylation
and degradation of the mRNA. The most studied roles of
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modulated during cellular stimulation by inactivation of
RNA decay-promoting proteins such as zinc-ﬁnger protein,
tristetraprolin (TTP) [4], K-homology splicing-regulatory
protein (KSRP) [5], butyrate response factor 1 and 2 [6],
and certain gene products of the AU-rich element (ARE)/
poly(U)-binding/degradation factor 1 (AUF1) [7]. The
mRNA stability can be enhanced by the activity of mRNA
stabilization-promoting proteins notably the human antigen
R (HuR). ARE-mediated changes in mRNA stability are
important in processes that require transient responses such
as cellular growth, defense to pathogens, cardiovascular
toning, and external stress-mediated pathways. Stabiliza-
tion of the ARE-mRNAs can cause prolonged responses
that subsequently may lead to undesirable, e.g., diseased,
states including chronic inﬂammatory diseases and cancer.
ARE-genes in inﬂammation and cancer
A number of important ARE-genes are commonly involved
in inﬂammation and cancer (Table 2). Different functional
categories and sequence classes of ARE genes are repre-
sented in these genes which regulate processes underlying
inﬂammation and cancer. These genes include cytokines,
chemokines, growth factors, transcriptional factors, RNA-
binding proteins, and others. The following is an appraisal
of notable examples of ARE-genes that have been widely
studied for their involvement in inﬂammation and cancer.
Tumor necrosis factor in chronic inﬂammatory
conditions and cancer
Tumor necrosis factor (TNF-a) is an AU-rich mRNA
coding gene (ARE-gene) that has well-validated ARE.
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Fig. 1 ARE-genes in inﬂammation-cancer crosstalk. Infectious
agents or their products, such as endotoxin, and chronic irritations
stimulate inﬂammatory and immune system cells such as the
macrophages to release pro-inﬂammatory cytokines. Many of these
cytokines are encoded by AU-rich mRNAs. In a chronic inﬂammation
setting, several signaling pathways that lead to stabilization of ARE-
mRNAs are continually activated leading to sustained production of
the cytokines. In a cancer-associated microenvironment, these
cytokines can promote the several processes that underlie cancer,
including tumor growth, resistance to apoptosis, angiogenesis,
invasion and metastasis. In turn, tumor cells themselves can release
chemokines and other mediators that amplify the inﬂammatory
response by attracting further inﬂammatory cells and stimulating
further ARE-gene expression of cytokines and growth factors.
Conditions in the tumor microenvironment such as hypoxia can also
trigger the expression of ARE-mRNAs of pro-inﬂammatory cyto-
kines, chemokines, and growth factors
Table 1 Common signaling pathways regulating inﬂammation and
cancer
JAK-STAT pathway
Mitogen-activated protein kinase pathway
NF-jB pathway
PI3-AKT3 pathway
Protein kinase C
Toll-like receptor pathway
Wnt signaling pathway
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expression of many inﬂammatory mediators including
chemokines. In addition to inducing transcription of a
number of ARE-genes, such as interleukin-8 (IL-8), IFN-c
induced IP-10 (CXCL-10), and colony stimulating factors,
TNF-a also mediates post-transcriptional regulation by
increasing the stability of their mRNAs [8, 9]. Notable
evidence on the role of ARE in TNF-a pro-inﬂammatory
action comes from studies of mice with targeted deletion
of the ARE in the TNF-a gene [8]. Here, chronic
Table 2 Non-exhaustive list of ARE-genes with evidence of involvement in both inﬂammation and cancer
Symbol Name ARE
a Inﬂammation Cancer
BCL2 B-cell CLL/lymphoma 2 III Inﬂammatory response Oncogenesis, apoptosis
CFOS c-fos III Inﬂammatory response Oncogenesis
CCND1 Cyclin D1 V Oncogenesis, maintenance
CXCL-1 GRO-a I Chemotaxis Oncogenesis, maintenance
ET2 Endothelin-2 IV Chemotaxis, cell–cell signaling Maintenance
EGF Epidermal growth factor V Inﬂammatory response Maintenance, angiogenesis, Invasion
EREG Epiregulin V Cytokine response Maintenance, angiogenesis
EGFR EGF receptor U-rich Cytokine response Cell growth, maintenance
FGF2 Fibroblastic growth factor 2 V Chemotaxis Cell growth, migration angiogenesis
CCL2 MCP-1 U-rich Chemotaxis Migration
CCL3 MIP-1a IV Chemotaxis Migration
CSF2 GM-CSF I Cytokine response Hematopoiesis, maintenance
CXCL-1 (Melanoma growth stimulating
activity, alpha), GRO-a
II Inﬂammatory response,
chemotaxis
Cell growth, maintenance
ELAVL1 HuR III Cytokine response RNA-binding, cell growth angiogenesis,
metastasis
F3 Tissue factor IV Coagulation Invasion, angiogenesis
SLC2A1 Glucose transporter 1 (Glut1) U-rich Inﬂammatory response Maintenance
HIFA Hypoxia induced factor-a III Transcription, inﬂammatory response Hypoxia response, angiogenesis
IL-1b Interleukin-1 II Inﬂammatory response Maintenance, metastasis
IL-6 Interleukin-6 IV Inﬂammatory response Cell growth, maintenance
IL8 Interleukin-8 III Chemotaxis Angiogenesis
LTA Lymphotoxin III Inﬂammatory response Oncogenesis
MMP13 Collagenase 3 (Matrix
metalloproteinase-13)
V Inﬂammatory response Invasion, metastasis
NOS Inducible nitric oxide synthase V Inﬂammatory response DNA damage
PDGFB Platelet-derived growth factor B IV Chemotaxis Oncogenesis, maintenance
PFKB3 6-phosphofructo-2-kinase/fructose-2,
6-iphosphatase 3
III – Carbohydrate metabolism,
maintenance
PLAU Urokinase plasminogen
activator (uPA)
IV Inﬂammatory response,
chemotaxis
Invasion, metastasis, angiogenesis
PLAUR UPA receptor V Chemotaxis Invasion, metastasis
PTGS2 Cyclooxygenase (COX-2) III Inﬂammation, motility Angiogenesis
PTHLH Parathyroid hormone-like hormone V Inﬂammation Maintenance
SCL2A1 Glut1 receptor V Inﬂammatory response Glycolysis, maintenance
SERPINE Plasminogen inhibitor activator 2 V Adhesion, coagulation Invasion, metastasis
SELE E-selectin III Leukocyte adhesion, migration Migration, metastasis
TNF Tumor necrosis factor a III Inﬂammation, cell–cell communication Cell growth, maintenance
VCAM Vascular cell adhesion molecule-1 III Leukocyte rolling Metastasis
VEGF Vascular endothelial growth factor IV Chemotaxis Hypoxia response, angiogenesis
a ARE clusters are based on bioinformatics clustering previously described [36]
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bowel disease were observed. Further indirect evidence of
the role of ARE in TNF-a production and associated
inﬂammatory pathology is from studies on mice with tar-
geted deletion of ZFP36 that code for the ARE-mRNA
destabilizing protein, TTP; the mice exhibit severe
inﬂammatory syndrome, characterized by severe polyar-
ticular arthritis, myeloid hyperplasia, autoimmunity,
dermatitis, conjunctivitis, glomerular mesangial thicken-
ing, and cachexia [9]. These pathologies are largely the
result of increased stability of the mRNAs for TNF-a and
GM-CSF and thereby increased secretion of these cyto-
kines [8–10].
Despite the notion of its name as tumor necrosis protein,
TNF-a is in fact a pro-tumor molecule in a number
of cancers (reviewed in [11]). Blockage of TNF-a in
mice models results in: failure of hepatitis to develop
hepatocellular carcinoma [12], reduction of colorectal
carcinogenesis associated with chronic colitis [13], inhi-
bition of pancreatic tumor growth and metastasis [14], and
promotion of epithelial ovarian cancer [15]. Other possi-
bilities of TNF-a as a cancer promoter are also shown with
other types of cancer [11]. It can act as a growth factor in
certain leukemias and lymphomas [16]. Thus, TNF-a is
involved both in inﬂammation and cancer and provides one
of the links between chronic inﬂammation and, in cancer,
at least certain tumor types.
Colitis-associated cancer is a progression from inﬂam-
matory bowel disease, and thus it is one of the best
examples of inﬂammation-induced cancer situations. It has
been demonstrated that TNF-a can induce the epithelial-
to-mesenchymal transition of colon carcinoma [17]. Drug-
induced colitis that leads to tumors is associated with
increased TNF-a secretion; in TNF-Receptor p55-knockout
mice, reduced mucosal damage, reduced inﬁltration of
macrophages and neutrophils, and attenuated subsequent
tumor formation are clearly seen [13]. In addition, mono-
cyte chemoattractant protein-1 (CCL2) plays a role in
colitis-associated colon tumors, and this could be mediated
by the expression of cyclooxygenase (COX-2) [18].
Involvement of COX-2 and VEGF in inﬂammation
and cancer
COX-2, a prostaglandin synthase enzyme, is an important
AU-rich mRNA which codes for Class 2 ARE (Table 2).
COX-2 has two isoforms, both of which catalyze the com-
mittedstepintheprostaglandinproductionpathway;COX-1
is present under basal conditions while COX-2 is an induc-
ible form by many inﬂammatory and growth promoters that
result in prostaglandin synthesis associated with inﬂamma-
tion and cancer. Nonsteroidal antiinﬂammatory inhibitor
drugs (NSAIDs) such as aspirin and indomethacin inhibit
both COX-1 and COX-2 while newer generations of NSA-
IDs selectively inhibit COX-2.
The increased activity of COX-2 is associated with colon
and other cancers, and promotes cellular proliferation,
resistance to apoptosis, angiogenesis, and metastasis [19–
21]. The inﬂammatory cells in the tumor microenvironment
contribute further to COX-2-mediated tumorgenesis via
induction of factors and cytokines that increase COX-2
gene expression which involves ARE-mediated mecha-
nisms. Other pro-inﬂammatory ARE-genes such as TNF-a,
IL-1, platelet derived factor (PDGF), vascular endothelial
growth factor (VEGF), and others can upregulate COX-2,
and, thus, inﬂammation ampliﬁes cancer through the
cytokine induction of COX-2 (Fig. 1).
Another important ARE gene that mediates both
inﬂammation and cancer is VEGF. VEGF is upregulated
during inﬂammatory response to increase blood supply,
and, therefore, increases in oxygen, nutrients, and inﬁl-
trating leukocytes, to the site of inﬂammation for lesion
repair. The source of VEGF is the leukocytes themselves
and endothelial tissues, and both can promote angiogenesis
of tumors. VEGF can promote inﬂammatory intestinal
angiogenesis and leukocyte adhesion during inﬂammatory
bowel syndrome [22] which can lead to colon cancer.
VEGF is potently induced by the hypoxia-induced factor,
HIF1a, a transcriptional factor and also an ARE-gene.
Hypoxia is a prominent feature of malignant tumors that is
characterized by angiogenesis and vascular hyper perme-
ability. HIF-1a is constitutively overexpressed in several
cancers as a result of hypoxia and induces VEGF mRNA
stability [23]. Pro-inﬂammatory cytokines, in the tumor
microenvironment, such as TNF-a and IL-1, activate
HIF1a. HIF1a, as result of hypoxia during tumor expan-
sion, can act as an inﬂammatory mediator, and has been
shown to have a role in leukocyte migration and in stromal
inﬂammatory cells [24, 25].
Vascular endothelial growth factor triggers the expres-
sion of urokinase activator, uPA, a serine protease, and its
receptor, uPAR, which is also an ARE-gene; uPA converts
plasminogen to plasmin that leads to the degradation of the
extra-cellular matrix, an important component of the
invasion and metastasis. The increased activity of uPA and
its receptor has been associated with invasiveness in a
number of tumors [26]. Another related angiogenesis-pro-
moting protein is IL-8, a member of the inﬂammatory
chemokines, a group of cytokines that are involved in
chemotaxis of leukocytes to inﬂamed regions. IL-8 can
promote angiogenesis and metastasis in a number of can-
cers [27, 28]. Thus, in general, chemokines can amplify
cancer processes in which tumor-associated leukocytes can
release chemokines and growth factors that further main-
tain or promote tumor growth and survival. Certain
chemokines can act as growth factors and some of these
2940 K. S. A. Khabarchemokines are coded by ARE-genes such as IL-8 and the
GRO family which play a role in melanoma growth and
metastasis [29].
Other pro-inﬂammatory cytokines and mediators such as
IL-1, IL-6, and inducible nitric oxide synthase (iNOS) play
roles in cancer (Table 2). Overexpression or prolongation
of iNOS due to chronic inﬂammation can cause cellular
injury in arthritis or colitis-promoting tumors by inducing
DNA damage and cellular proliferation [30]. Pro-inﬂam-
matory cytokines, many of which are coded by ARE-genes,
are released from the tumor micro-environment favoring
the initiation and progression of cancer. These happen
when these cytokine ARE-genes themselves tend to exert
further ARE-mediated post-transcriptional effects that lead
to production of the growth factors in neighboring cells
(Fig. 1). Having described the role of ARE-genes in
chronic inﬂammation and cancer, the next section addres-
ses the ARE and their sequence structure–function
relationships.
AU-rich elements and their sequence characteristics
Sequence characteristics of ARE classes
The ARE are a heterogeneous class of adenylate uridylate-
rich sequences that range from loosely deﬁned U-rich or
AU-rich sequences to well-deﬁned repeats of overleaping
pentamers of AUUUA or the nonamer UUAUUUAUU.
The latter motif or its variation UUAUUUAWW is con-
sidered the minimally functional ARE sequence; a stronger
effect on RNA stability is obtained with two overlapping
copies of this nonamer [31–35]. The pentamer AUUUA in
non-AU context is not functional, and, as a matter of fact, it
is ubiquitous in many mRNAs, regardless of the mRNA
region. With computational biology analysis of labile
mRNAs, WWWUAUUUAUWW is the most consensus
motif in labile AU-rich mRNAs and is highly speciﬁc to
the 30UTR when compared to other regions of the mRNA,
e.g., 50UTR and coding regions [36]. This motif, including
variations around the core pentamer, is the basis for
building up the ARE-mRNA database (ARED). The ARED
motif is closely related to the Class 2 ARE based on the
Chen et al. classiﬁcation where Class 1 ARE have dis-
continuous nonamers and Class 2 ARE have at least two
overlapping copies of the nonamer [31]. Both class II ARE
and ARED motifs are found preferentially in labile tran-
scripts in different cell types that are stimulated with
different ligands including ﬁbroblasts, hepatocytes, and
immune system-type cells such as a-CD3- or CD28-acti-
vated T cells and endotoxin-induced monocytes; thus, in
general, genome-wide studies conﬁrm the association
between these ARE and rapid mRNA decay [3, 37–39].
ARE recognition
Further deﬁnition and minimal function of the ARE motif
was sought by interaction studies of synthetic RNA mol-
ecules and RNA-binding proteins. It appears that from the
various studies that functional ARE can exist as either
linear non-structured RNA molecules or as structural RNA,
i.e., stem-loop structures [40–42], as in the case of short
ARE or certain non-ARE mRNA decay elements. In
the ﬁrst case, the minimally functional linear ARE,
UUAUUUAUU, or the 13-bp ARED motif is required. The
RNA motif NNUUNNUUU for HuR binding is also
functional as linear conformation or as a linear segment
within a secondary structure; the latter conformation pro-
motes further recognition by the RNA-binding protein [40–
43]. This RNA motif is still within the 13-bp ARED motif
WWWUAUUUAUWWW, and also within the linear ARE
segment within a structured RNA of HuR targets that
contains UUNNUU(G/U)UUWW [43]. Similarly, work
with the neuronal RNA-binding protein HuD shows that
the three RNA-binding domains interact with a minimal
13-bp motif that includes UU(AUUU)NAUU [44]. Further
evidence of ARE functionality is from work on interactions
of synthetic RNA molecules with TTP also showing that as
small as UAUUUAU and UUAUUUAUU can bind TTP
and that the 13-bp motif ARE has a strong afﬁnity for
TTP [45, 46]. The adenylate residues in the pentamer
(AUUUA)or hexamer (AUUUUA) core are important for
TTP binding but not necessarily for Hu proteins, which
unlike TTP, can bind a U-rich tract [44–46]. Large-scale
analysis of ARE based on reporter live cell-based assays
are still needed to correlate many of these ﬁndings with
actual functional effects of ARE variations on RNA and
protein levels. A different approach to delineate the ARE
and other mRNA destabilization sequence elements has
been adopted in recent years in which target mRNAs
physically associated with RNA-binding protein are pro-
ﬁled using microarrays followed by RNA motif derivation
bioinformatics [43, 47–49]. These motifs are still charac-
terized by short U-rich dinucleotides and clusters but may
inherit authenticity of the RNA-binding protein association
with its target transcripts since not all the target mRNAs
harbor the identiﬁed sequence signature.
Length of the 30UTR and the ARE
Although the ARE can exist in other regions of the mRNA,
though to a much lesser extent, such as 50UTR and coding
regions, the 30UTR are the main source of ARE [36]. The
50UTR are well known for their translation regulatory role
in cellular and viral mRNA including cap-dependent and
internal ribosomal entry site (IRES)-mediated processes
[50] but can have a function in mRNA decay, for example
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been reported to bear mRNA instability motifs, though not
typical of ARE, such as those in interferon-b and CD38
coding regions [51, 52].
The 30UTR length can be a determinant factor in RNA
stability. It appears that the 30UTR of ARE-mRNA is
longer than non-ARE mRNAs such as those of house-
keeping genes [53–55]. Longer 30UTR tend to have a
higher proportion of miRNA targets, indicating the higher
order of post-transcriptional regulation complexity. Certain
miRNAs may synergize with ARE on the same 30UTR by
reducing RNA stability and/or translation [56]. Alternative
polyadenylation that results in differential expression of
short and long 3’UTR is widespread in the transcriptome.
This length alteration can reﬂect functional responses
towards miRNAs, ARE involvement, and RNA-binding
proteins. Short 30UTRs escape at least a part of miRNA-
mediated suppression and ARE-mediated decay [57, 58].
Indeed, this 30UTR length-mediated control has a func-
tional outcome on protein levels and activity including
cellular growth [57, 58].
The length of ARE itself, e.g., the number of the over-
lapping pentamer, AUUUA, may contribute to the mRNA
half-life. Experimentally, it has been shown that the num-
ber of ARE pentamers correlate with the half-life of ARE-
mRNAs [59]. Bioinformatics clustering of ARED resulted
in ﬁve groups, I–V, that include mRNAs whose 30UTRs
have ﬁve, four, three, and two consecutive AUUUA
pentamers, and single AUUUA pentamer in ﬂanking
AU-context, respectively. The number of these transcripts
in these groups increased dramatically from group I to
group V. The last group is heterogeneous and large and not
necessarily functional while the key characteristic of other
groups’ transcripts is the presence of the WWAUUUA
UUUAWW sequence which likely RNA-binding proteins
such as TTP could bind to, thus resulting in a large number
of potential TTP and other RNA-binding protein mRNA
targets [60]. In a detailed analysis of ARE-mRNA half-
lives in endotoxin-stimulated monocytes and activated
T cells, longer ARE are associated with shorter half-lives
[37, 38].
The ARE are conserved among different species [1].
However, orthologs may bear different ARE arrangements
such as the number of overlapping pentamers in AU-rich
clusters. Although a signiﬁcant proportion ([25%) of
human genes differ in their ARE patterns from mouse and
rat transcripts [1]. This suggests that the ARE-mediated
post-transcriptional control for a given gene may be func-
tional in one organism but not in another. The
heterogeneity may also reﬂect diversity of the AU-rich
binding proteins and their protein–protein interactions. In
general, the ARE are the most studied and validated
mRNA destabilization elements. However, other mRNA
destabilization elements do exist [3]. The existence of the
GU-rich element motif, UGUUUGUUUGU, which may
mediate mRNA decay, in a number of labile mRNAs has
been recently shown [61]. Altogether, it is clear that there
are several mRNA decay elements in the 30UTR which
may explain the repertoire of RNA-binding proteins that
are thought to exist in thousands.
Regulation of ARE-gene expression: RNA-binding
proteins
The RNA-binding proteins play key roles in each of the
processes in which the ARE are involved including RNA
processing, export, localization, degradation, and transla-
tion. At default, the ARE maintain the instability behavior
of many ARE-mRNAs and have an inhibitory action on
translation [62, 63]. In certain conditions, the ARE can
switch into a translation activation signal, such as in the
case of TNF-a mRNA translation during serum starvation
that leads to cell cycle arrest [64]. Not all the RNA-binding
proteins that affect post-transcriptional regulation of genes
are discussed here. The HuR and TTP proteins are the most
studied RNA-binding proteins in the context of chronic
inﬂammatory conditions and cancer and regulate ARE-
genes involved in these diseases. Thus, more emphasis on
these two proteins is given throughout this review.
The tristetraprolin and HuR RNA-binding proteins
TTP is a part of the zinc-ﬁnger family proteins consisting
of conserved Cys-Cys-Cys-His domain and comprising
TTP (also known as ZFP36, TIS11, G0S24 and NUP475),
ZFP36L1 (TIS11b, cMG1, ERF1, BRF1 and Berg36) and
ZFP36L2 (TIS11d, ERF2 and BRF2) [65]. Mutation of
either of the two zinc-ﬁngers of TTP by a single-point
mutation (Cys to Arg), e.g., C124R mutant, fails to bind
TNF-a 30UTR and its ARE [66]. Well-established mRNA
targets for TTP binding are involved in inﬂammation
include the mRNAs of TNF-a, GM-CSF and IL-3 [10, 67–
69]. Furthermore, two targets of TTP that are related to
both inﬂammation and cancer have been identiﬁed, namely
COX-2 [70, 71] and VEGF [72]. A polyadenylation ARE-
mRNA transcript variant of HuR has recently been
uncovered and is responsive to HuR auto-regulation and to
wild-type TTP mRNA decay action but not to the zinc-
ﬁnger mutant (C124R)[73]. Transcriptome analysis using
RNA from TTP wild-type and knockout cells identiﬁed
further mRNA targets [55, 74].
Human antigen R is a member of the mammalian
homologues of embryonic lethal abnormal vision (ELAV)
proteins comprising a group of RNA-binding proteins ﬁrst
described in Drosophila [75]. It is predominantly nuclear,
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binds selected mRNAs and causes their stabilization [76].
HuR and other members of ELAV proteins possess three
RNA-recognition motifs through which they bind with high
afﬁnity to speciﬁc mRNAs bearing AU- and U-rich
sequences affecting their stability and/or translation [77–
81]. The array of HuR target mRNAs is large, as analyzed
by proﬁling of mRNAs that are bound to HuR protein
which include many cytokines, growth factors, cell-cycle
regulators, and many others [43, 80, 82]. Recent work,
particularly with conditional deletion of HuR in mice,
reveals complex and essential roles of HuR in development
including thymic T cell maturation, placental branching
morphogenesis, spleen ontogeny, intestinal integrity, and
hematopoietic progenitor cell survival [83–85].
Tristetraprolin and several other RNA-binding proteins
such as BRF1, KSRP, and AUF1 appear to function by
targeting AU-rich mRNA to the exosome, a multiprotein
complex with 30–50 exoribonuclease activity representing a
major degradation scheme in eukaryotes [86]. When
phosphorylated, these RNA-binding proteins are com-
plexed with 14-3-3 proteins that inﬂuence their sub-cellular
localization and mRNA decay activity [6, 87, 88]. The
14-3-3 proteins also protect RNA-binding proteins such as
TTP from de-phosphorylation by the protein phosphatase
2a40, resulting in further stabilization of ARE-mRNA [89].
ARE binding proteins can also function by recruitment of
degradation factors other than the exosome [90, 91].
Another pathway of 50–30 decay can also occur during
degradation of ARE-mRNAs in the cytoplasmic RNA foci
called processing bodies [92].
In tumor cells or during the cell cycle, and also in
response to inﬂammatory stimuli, HuR may stabilize certain
mRNAs by the displacement or inhibition of factors such as
TTP, KSRP or AUF1 that speciﬁcally cleave or deadenylate
these mRNAs. Associations of KSRP and AUF1 p45, or
KSRP and HuR, allow ﬁne tuning of ARE-mRNA stability
[93, 94]. A speciﬁc example is that siRNA-mediated
knockdown of HuR led to larger AUF1 association with
cyclin D and p21 mRNAs [80]. Ectopic expression of HuR
overcomes TTP-mediated destabilization of IL-3 mRNA
and HuR mRNA in an ARE-dependent manner [69, 73].
CUGBP2 can override HuR and suppresses COX-2 mRNA
translation [95]. Pro-inﬂammatory cytokines can reduce
KSRP binding and enhance HuR binding to iNOS 30UTR-
ARE leading to its stabilization [96]. Thus, it appears that
HuR antagonize ARE-mRNA decay-promoting proteins
during chronic inﬂammation and cancer.
Other RNA-binding proteins
AUF1 is another characterized RNA-binding protein with
two quasi-RRM domains that consists of four protein
isomers of 37, 40, 42, and 45 kDa differing in their ter-
minal domains and their RNA-binding activity [97]. AUF1
binds to and destabilizes both inﬂammation and cancer-
associated ARE-mRNAs such as c-myc, TNF-a, GM-CSF
and others [98, 99]. Like TTP, AUF1 acts as another
negative feedback mediator of the innate response to
inﬂammatory stimuli such as endotoxin; LPS challenge in
AUF1-knockout mice displays symptoms of severe endo-
toxic shock due to overproduction of TNF-a and IL-1b
[99]. However, in certain conditions, certain isoforms of
AUF1 or during effects on certain ARE classes, AUF1 can
stabilize mRNAs, for example during heat shock, and in
certain cancer situations such as in the case of cyclin D1
and c-fos mRNA [98, 100]. The fragile X mental retarda-
tion, autosomal homolog 1 (FXR1), is a K–H type RNA-
binding protein that interacts with TNF-a ARE to either
repress or upregulate mRNA translation during serum
growth or starvation conditions, respectively [64, 101].
FXR1 knockout and conditional knockout mice exhibit
muscle wasting that may be attributed to increased TNF-a
mRNA translation [101]. A recent review describes in
detail the role of the miRNP (microribonucleoprotein)-
associated proteins FXR1 and Argonaute 2 as effector
molecules that bind the ARE to activate TNF-a mRNA
translation [102].
These examples demonstrate that there is a complex
interplay of RNA-binding protein in the 30UTR and ARE
regions that determines the outcome of the mRNA half-life
as affected by external stimuli. Further details on the
function of the RNA-binding proteins are given in the next
section. What are the common signaling pathways that
operate during chronic inﬂammation and cancer and how
do they affect RNA-binding proteins interactions with
ARE?
Common ARE-mediated signaling pathways
in inﬂammation and cancer
A signiﬁcant link between inﬂammation and cancer arise
from the molecular and physiological observations of the
effect of NSAIDs; attenuation of chronic inﬂammation by
NSAIDs corresponds to lower incidence of cancer, notably
colon cancer. Thus, one may conclude that signaling
pathways or at least part of them—that are targeted by
NSAIDs—are operative in both inﬂammation and cancer.
One of these is the NF-jB pathway (recently reviewed in
[103, 104]). Many of the cancer-promoting proteins are
ARE-genes in which their gene transcriptions are triggered
by NF-jB (Fig. 1). Stimulation of these genes by pro-
inﬂammatory cytokines themselves or ligands of toll-like
receptor initiates signaling that diverges into transcriptional
(NF-jB) and post-transcriptional regulatory pathways
AU-rich elements in inﬂammation and cancer 2943[105, 106]. The latter pathways constitute the mitogen-
activated protein kinase (MAPK), phosphatidylinositol
3-kinase (PI3 K)-AKT, Wnt/b-catenin pathways, and
others [6, 37, 87, 107]. Since signaling pathways are
deregulated in cancer and common with those occurring
during chronic inﬂammatory conditions, it is likely these
continually active signaling pathways lead to changes in
the expression and localization of RNA-binding proteins
that favor tumorgenesis and chronic inﬂammation. Most of
the studies on signaling pathways have been performed
with transcriptional induction in contrast to post-tran-
scriptional modulation. However, the p38 MAP kinase and
PI3 kinase pathways are the most studied signaling path-
ways regulating ARE-mediated post-transcriptional events
(Fig. 2). That does not mean the other pathways are not
involved since there are indeed scattered but non-extensive
reports on their involvements (Table 1).
The mitogen-activated protein kinase pathways
Inﬂammatory stimuli activate the three MAPK major
pathways: extracellular signal-regulated kinase (ERK),
c-jun N-terminal kinase (JNK), and p38 MAPK pathways.
Abnormalities in signaling pathways of MAPK, particularly
the ERK pathway, are associated with cancers in mice and
humans (reviewed in [108]). Constitutive activation of ERK
can occur with activation of Raf and Ras oncogenes that are
commonly deregulated in cancer. The JNK pathway can be
activated in certain cancer types [109] and has also been
demonstrated in the stabilization of VEGF and iNOS [110].
Downstream of MAPK are other kinases such as the
MAPK-activated protein kinase 2 (MAPKAPK2 or MK2)
which regulate both transcriptional and post-transcriptional
gene expression. The p38 MAPK pathway activation in
inﬂammation is one of the most common pathways that
regulate mRNA stability in multiple cell types. This path-
way is central to the stabilization of many ARE-mRNA
involved in inﬂammation and cancer, including COX-2,
TNF-a, IL-3, IL-6, IL-8, macrophage inhibitory protein 1
(MIP1), GM-CSF, VEGF, c-fos, and uPA [69, 111–116].
The pro-inﬂammatory cytokines, IL-1a and TNF-a, have
been found to stabilize a signiﬁcant number of cytokines
and chemokines including CXCL-10 (IP-10), GRO pro-
teins, and fractalkine (SCYD1), and several genes involved
in regulation of inﬂammatory responses such as TNFAIP3,
NFjBaI, and mannose-binding lectin (MBL2) [117–119].
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Fig. 2 Common signaling pathways in inﬂammation and cancer
including those regulating ARE-gene expression and mRNA stability.
Microbial stimuli, inﬂammatory and tumor inducers, and ARE-gene
products themselves such as certain growth factors and pro-inﬂam-
matory cytokines trigger a number of signaling pathways. One of
those is the p38 MAPK pathway that leads to phosphorylation and
inactivation of the activity of the RNA decay-promoting proteins such
as TTP and KSRP. This results in stabilization of ARE-mRNAs that
are involved in chronic inﬂammation and cancer. The RNA-binding
stabilizing protein, HuR, is able to compete with the RNA-binding
proteins such as TTP and AUF1 for the same mRNA targets;
however, it can also act independently on mRNA targets for
promoting mRNA stabilization
2944 K. S. A. KhabarThese cytokines and many others are regulated by the p38
MAPK signaling and its target, MK2, to trigger the ARE-
mRNA stabilization. Not all ARE-mRNAs, regardless of
the ARE class, are targets for the MAPK p38 pathway [37].
Thus, the p38 MAPK pathway is not essential for all ARE-
mRNAs and appears to be also dependent on the stimulus.
Cooperative action of p38 MAPK and ERK pathways can
be necessary for optimal ARE-mRNA stabilization, par-
ticularly in the case of inhibition of TTP [120]. Another p38
MAPK downstream target with structural and functional
similarity to MK2 is MK3; it is thought to cooperate with
MK2 in TNF-a mRNA stabilization [121].
Effect of p38 MAPK on TTP and HuR functions
Activation of the p38 MAPK pathway leads to MK2-
mediated phosphorylation of TTP and KSRP leading to
loss of function of these RNA-binding proteins, e.g.,
reduced afﬁnity to ARE regions, and subsequently ARE-
mRNA stabilization (Fig. 2)[ 122–124]. A detailed role for
MK2 is demonstrated, for example, in the stability of IL-8
mRNA since mutants of MK2 interfere with IL-8 mRNA
stability [116]. Selective activation of the p38 MAPK
pathway by MAPK kinase 6 induces mRNA stabilization
of IL-8 [112]. MK2 can regulate IL-6 at the levels of
mRNA stability, and of TNF-a mainly through TNF-ARE-
dependent translational control [125]. In vitro evidence
shows that TTP can be directly phosphorylated by either
p38 or MK2 potentially modifying mRNA destabilizing
activity of TTP [121, 122]. Activation of p38 MAPK
pathway by pro-inﬂammatory cytokines such as IL-1a can
phosphorylate KSRP leading to loss of its binding activity
to ARE and subsequently mRNA stabilization [93, 124].
The MK2-knockout mice with induced collagen arthritis
exhibit decreased disease incidence and severity, associ-
ated with reduced TNF-a and IL-6 serum levels [123].
Inhibition of p38 using the pharmacological inhibitor
SB203580 (SB), or by expressing dominant negative MK2,
abolishes endotoxin-induced COX-2 mRNA stabilization
and leads to rapid degradation of COX-2 mRNA [124–
126]. Recent evidence shows that p38 regulates stability of
several ARE-mRNAs, e.g., COX-2, IL-1a, IL-6, and IL-10
exclusively through TTP phosphorylation such as in mur-
ine bone marrow-derived macrophages [126].These above
studies and others offer strong evidence for the p38 MAPK
regulation of ARE-mRNA stability and the association
with loss of TTP function.
The p38 MAPK activation further results in hosting of
the RNA stabilizing proteins such as HuR in place of the
displaced RNA decay-promoting proteins. The p38 MAPK
may also phosphorylate ARE-stabilizing proteins such as
HuR which could compete with the destabilizing proteins
such as TTP as suggested in studies on the regulation of
IL-3 mRNA decay [127]. The p38 MAPK regulates HuR
localization and subsequently HuR mRNA targets that are
involved in chronic inﬂammation and cancer such as uPA
and COX-2 [128–130]. Certain signaling pathways
converge or cooperate with MAPK pathways in the ARE-
mediated post-transcriptional control such as the PI3-AKT
and b-catenin pathways (Fig. 2); both of these and oth-
ers are discussed in the next section. For further details
on MAPK and post-transcriptional gene regulation, sev-
eral excellent reviews have appeared in the literature
[131, 132].
The PI3-AKT pathway
The PI3 kinase pathway comprises lipid and protein kina-
ses that regulate numerous biological processes, including
cell growth, differentiation, survival, chemotaxis, and
metabolism. As a result of ligand engagement of a number
of receptors for integrin, tyrosine kinases, cytokines, and
growth factors, activation of the PI3 kinase catalyzes the
addition of a phosphate group to the phosphatidylinositol
lipids (PIP2), generating different 30 phosphorylated
products (PIP3) that act as second messengers. PIP3 leads
to membrane recruitment of the cystolic AKT3 to the
membrane and its activation (Fig. 2). Activated AKT3
(also called protein kinase B) is a central serine-threonine
kinase effector that participates in the various biological
processes such as the cell cycle progression and survival
(e.g., reduced apoptosis). Deregulation of the PI3 K sig-
naling pathway has been foundto be frequently associated
with cancer, and simple overexpression of wild-type
PI3 Ka can be sufﬁcient to induce an oncogenic phenotype
in cultured cells [133]. Mutations in the PI3 kinase com-
ponents, genetic alterations in tyrosine kinase receptors, or
loss of PI3 kinase negative regulator, PTEN, can be
detected in a large number of human tumors. Several
tyrosine kinase growth factor oncoproteins activate the
PI3-kinase pathway including EGFR (an ARE-gene),
PDGFR, VEGFR, stem-cell factor (kit, an ARE-gene) and
hepatocyte growth factor (met). As a result, increased PI3
kinase activity in cancer cells and subsequently increased
growth and survival are observed (reviewed in [134]). In
inﬂammation, the PI3 Kinase pathway drives certain
inﬂammatory processes such as neutrophil chemotaxis,
mast cell and eosinophil migration, and degranulation.
Inﬂammatory cytokines such as TNF-a can activate the
PI3-AKT pathway which subsequently leads to activation
of the NF-jB pathway, and this appears to be the case with
certain cell types [135]. The PI3 kinase pathway has been
shown to be involved in the mRNA stabilization of several
reporter genes linked to the ARE of IL-3, GM-CSF,
TNF-a, IL-2, and IL-6 [127, 136]. Hence, PI3 kinase
activation further ampliﬁes the processes underlying
AU-rich elements in inﬂammation and cancer 2945chronic inﬂammation and cancer partially by post-tran-
scriptional augmentation of cytokines and tyrosine growth
factors.
Other signaling pathways
Other signaling pathways which operate both in chronic
inﬂammation and cancer and also regulate ARE-dependent
post-transcriptional control of gene expression exist
(Table 1). For example, protein kinase C (PKC) activation
has been shown to increase COX-2 mRNA stability, and
this effect appears to be mediated by crosstalk with the
MAPK pathway [137, 138]. The Wnt b-catenin pathway
activation can stabilize ARE-mRNAs. For example,
b-catenin binds to the ARE region of the COX-2 mRNA
and increases its stability and interacts with HuR [139].
Further ampliﬁcation of the Wnt pathway can arise from the
action of pro-inﬂammatory prostaglandins, in particular
PGE2, produced by COX-2 [140]. The PI3-AKT pathway
can increase the stability of the b-catenin pathway by
inactivating the RNA decay properties of KSRP through
AKT-mediated phosphorylation at a unique serine residue
in KSRP, that results in association with the multifunctional
protein 14-3-3 and prevents KSRP interaction with the
exoribonucleolytic complex exosome [94].
Signaling pathways such as the NF-jB, STAT-JAK, and
b-catenin pathways activate transcription of RNA-binding
proteins or ARE-genes that are involved in chronic
inﬂammation and cancer which lead to post-transcriptional
effects. Increased transcription of HuR may be mediated by
a putative NF-jB binding site in the HuR promoter [141].
Thus, increased NF-jB activity during chronic inﬂamma-
tion and cancer may be associated with elevated HuR
transcription, and, subsequently, higher HuR-mediated
stabilizing effects on target mRNAs. Because of the
apparent heterogeneity of ARE sequences and interactions
with their binding proteins, it is expected that the hetero-
geneity also extends to the signaling pathways regulating
ARE-mediated events.
How do deregulated pathways in inﬂammation
and cancer affect ARE-mediated processes?
The various signaling pathways discussed above are dys-
regulated in chronic inﬂammation and cancer, either by
prolonged activation and/or by loss of negative feedback
control of mRNA expression (Figs. 1 and 2). One outcome
is alterations in the behavior of ARE-binding proteins due
to the signaling pathway aberrations; these events cause
overproduction of pro-inﬂammatory molecules and cancer-
promoting gene products. Further, defects in ARE-medi-
ated processes may arise by different mechanisms
including mutations in the ARE themselves, chromosomal
deletions of ARE regions, promoter silencing of
RNA-binding proteins, differential expression of miRNA
targeting ARE-genes or RNA-binding proteins, and dif-
ferential abundance of ARE-deﬁcient alternative mRNA
forms. The following summarizes these potential mecha-
nisms that affect ARE-mediated post-transcriptional
control, and the associated diseases of inﬂammation origin
and cancer.
Deregulation in expression and localization
of RNA-binding proteins
Overexpression of RNA-binding protein that tends to sta-
bilize AU-rich mRNAs such as HuR and certain isoforms
of AUF1 is observed in certain cancers. Also, under-
expression of RNA destabilizing proteins such as TTP can
lead to increase in AU-rich mRNAs that are involved in
chronic inﬂammation and cancer. Changes in localization
of the RNA-binding proteins towards a compartment that
facilitates their action comprise a possible deregulated
mechanism that leads to overexpression of the proteins
involved in chronic inﬂammation and cancer crosstalk.
Many RNA-binding proteins are nuclear-cytoplasmic
shuttling proteins that can translocate during activation.
During disease, an RNA-binding protein may be locked
into one compartment that becomes either active or non-
active, depending on the protein, and thus inﬂuences the
outcome of RNA turnover.
Alternations in the cellular localization and expression
of HuR
Human antigen R is predominantly nuclear, but during
cellular growth and activation, it translocates to the cyto-
plasm where it binds AU-rich mRNAs, including those
involved in inﬂammation and cancer such as VEGF, COX-
2, and IL-8, IL-6, and TNF- a, and promotes their mRNA
stabilization. In particular, HuR has the capacity to
upregulate many cell-cycle and pro-growth genes by
binding and stabilizing their mRNAs such as cyclins,
growth factors, and transcriptional factors. Several inde-
pendent lines of evidence strongly support the role of HuR
in promoting cellular growth. HuR knockdown of HuR by
siRNA or antisense vectors decreases cellular growth [142,
143]. Knockdown of HuR also leads to decreased cellular
growth and VEGF expression in colorectal cancer cells
[144]. miR-519 represses HuR translation, in turn reducing
HuR-regulated gene expression and cell division [145].
Further indirect evidence is that RNase L suppression of
cellular growth is associated with reduction in HuR mRNA
expression [146].
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pressed in tumor cells when compared to their normal
counterparts, with increased localization of HuR in cyto-
plasmic compartments. Breast, colon, gastric, prostate, and
ovarian cancers have been linked to overexpression of HuR
and increased cytoplasmic localization, when compared to
normal tissues [143, 147–150]. HuR is particularly seen in
higher amounts with advanced versus early tumors such as
in case of gastric tumors, glioblastomas, breast cancer, and
lung cancer [149, 151]. Cytoplasmic expression of HuR is
increased in urethane-induced neoplasia and in butylated
hydroxytoluene-induced compensatory hyperplasia in
mouse lung tissue [152]. However, certain studies have
shown that HuR overexpression may be limited to a small
sub-set of tumors [153]. Cytoplasmic but not nuclear HuR
expression is signiﬁcantly associated with tumor grade,
poor differentiation, and lymph node metastasis in non-
small cell lung cancer with increased levels of VEGF-C
[154].
In an epithelial to mesenchymal transition colon cancer
rat cellular model that undergoes invasive phenotype in
response to Ras and TGF-b, a synergistic effect is observed
with the stability of several ARE-mRNA including COX-2
and VEGF [155]. The VEGF mRNA is a target for HuR
binding and effect. It is associated with increased HuR
expression in different types of cancers; for example, major
HuR expression is detected in perinecrotic areas in which
VEGF, COX-2, and IL-8, all angiogenesis factors, are up-
regulated [151]. HuR overexpression and cytoplasmic
localization leads to binding to, and upregulation of, COX-
2 mRNA expression in a number of cancers [71, 156–159].
The highly invasive breast cancer cell line, MDA-MB-231,
which has increased constitutive levels of uPA, is due to
impairment in the ARE-mediated decay of uPA mRNA;
this is correlated with HuR overexpression and p38 MAP
kinase induction [113]. Thus, these many studies clearly
show consistent correlation of cytoplasmic localization of
HuR with tumor grade, tumor size, and patient survival in
many types of cancer tissues.
How is cytoplasmic localization of HuR promoted in
tumor cells? Certain signaling aberrations in cancer may
promote cytoplasmic HuR localization such as p38 MAPK
and PKC pathways. The overexpression of constitutively
active MK2 results in increased HuR cytoplasmic locali-
zation in the MDA-MB-231 invasive breast cancer line
[129]. HuR phosphorylation by p38 MAPK, cAMP kinase,
PKC, and cell-cycle G2-phase kinase Cdk1 can regulate
HuR shuttling and thus affect the mRNA stabilization
outcome [128, 160, 161]. Aberrations in the expression or
activity of these kinases in cancer can lead to changes in
HuR phosphorylation that favor cytoplasmic localization of
HuR. A detailed review on the role of phosphorylation in
HuR translocation, see [161].
Loss of TTP expression and function in cancer and chronic
inﬂammation
Continued secretion of cytokines and growth factors during
chronic inﬂammation and cancer contribute to a prolonged
state of activated pathways such as the MAPK pathway
that maintains mRNA stabilization by inactivation of
RNA-binding proteins that participate in mRNA decay
such as TTP and KSRP (Fig. 2). These events allow the
prevalence of HuR stabilizing action. Elevated HuR
expression occurs with the loss of TTP expression at an
early stage of colorectal tumorigenesis that is associated
with increased COX-2 expression [71]. TTP mRNA and
protein levels are signiﬁcantly decreased in tumors of the
thyroid, lung, ovary, uterus, and breast compared to non-
transformed tissues [153]. Loss of TTP is observed in the
highly metastatic breast tumor line, MDA-MB-231, that is
functionally associated with increased invasion and ele-
vated expression of uPA and uPAR mRNAs due to their
stabilization [162]. It is not necessarily that TTP levels are
reduced in order to observe reduced TTP-induced mRNA
decay, since phosphorylation of TTP due to aberration in
signaling pathways, such as overactivated p38 MAPK, is a
defect that is observed in several cancers. An example is
demonstrated with malignant gliomas in which TTP is
hyperphosphorylated due most likely to p38 MAPK acti-
vation [163]. Here, loss of TTP can be linked to
overexpression of TTP mRNA targets that are involved in
inﬂammation and cancer such as VEGF [163]. Since the
ERK pathway is overactivated in cancer, it is thought that
ERK activation results in phosphorylation of TTP, leading
to an increase in TTP mRNA targets such as VEGF [72].
Loss of TTP in hepatocellular carcinoma is thought to lead
to an increase in HIF1a, a key player in angiogenesis [164].
A possible mechanism of TTP deﬁciency in tumor cell
lines and tumors is silencing of TTP promoter due to
epigenetic alterations as a result of changes in DNA
methylation or altered chromatin [71]. Possible loss of TTP
and probably other ARE-mRNA decay-promoting proteins
is overexpression of miRNAs that target the mRNAs of
these proteins; the miR-29a which may be overexpressed in
breast cancer tissues can suppress TTP [165]. Thus, the loss
of post-transcriptional regulation due to decreased expres-
sion of mRNA decay proteins such as TTP can occur with
different mechanisms and allow enhanced expression of
common inﬂammation and cancer genes.
An indirect involvement of TTP dysfunction in chronic
inﬂammatory conditions may be deduced from the obser-
vation that the anti-inﬂammatory cytokine, IL-10, increases
TTP expression and subsequently reduces the pro-inﬂam-
matory cytokines, TNF-a and IL-1 [166]. Certain
IL-10 promoter polymorphisms that result in reduced
IL-10 production may be associated with a number of
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inﬂammatory bowel disease [167]. Thus, it is possible that
dysfunction in IL-10 production would lead to reduced
TTP levels and subsequently elevated pro-inﬂammatory
cytokines. Thus, the strong anti-inﬂammatory properties of
TTP can be explained by both direct targeting of pro-
inﬂammatory mRNAs for degradation and by helping the
potent anti-inﬂammatory cytokine, IL-10, to exert its
immunosuppressive effects. IL-10-deﬁcient mice develop a
range of auto-immune diseases, colitis and colorectal
cancer similar to the inﬂammatory bowel disease-associ-
ated cancer in humans [168, 169]. The role of IL-10 in
either promoting or inhibiting tumor growth in humans
may still be controversial and would require larger patient
data [170]. Since IL-0 mRNA itself is subject to decay
promotion by TTP [126], this suggests that ARE-mediated
decay is important for immune homeostasis.
Changes in alternative splicing and polyadenylation
Certain ARE-genes code for alternative polyadenylation
variants that have multiple poly(A) sites that may be
differentially used during inﬂammation and cancer. The
loss of the ARE in the 30UTRs due to changes in alter-
native splicing or polyadenylation pattern may lead to
overexpression of an undesirable pathway triggered by the
alternative transcript. The existence of two transcripts
generated by the use of alternative polyadenylation
sequences that differ in their 30UTRs and the differential
presence of ARE is found in a number of genes. Notably,
these are COX-2, cyclin D1, VEGF, ﬁbroblast growth
factor 2, and, recently, HuR [70, 73, 171–173]. In the
latter case, the different alternative variants have differ-
ential response to HuR-induced stabilization and
destabilization to TTP and other mRNA decay players
[73, 146]. Similarly, alternative splicing that result in
ARE and non-ARE form can also be differentially
regulated.
The COX-2 gene codes for two alternative polyade-
nylation variants that differ in their 30UTR length with
different patterns of post-transcriptional regulation [70,
171]. Both the major transcripts of COX-2 gene, 2.8- and
4.6-kb mRNAs, contain a highly conserved ARE region
(cluster III ARE, Class 2) in the proximal part of the
30UTR. However, the longer transcript contains an addi-
tional conserved ARE region (Class 1 ARE). These
different transcripts respond differentially to TTP-medi-
ated RNA decay [70, 171]. In certain cancer types, the
abundance of expression of the shorter transcript is
higher, which may contribute to the overexpression of
COX-2 in cancer and during inﬂammatory activation [70,
171–173]. In some primary tumors and in cell lines,
cyclin D1 mRNAs of smaller size—due to chromosomal
alterations that lead to deletion of ARE-30UTR in CCND1
gene—can be detected and substantially increased in
mantle cell lymphoma cells [173]. Cyclin D1 overex-
pression is known to perturb the G1-S transition of the
cell cycle and thereby contributes to tumor development.
HuR mRNA also has several alternative polyadenylation
variants, with the least abundant being a long 30UTR
transcript that harbors an ARE and is responsive to HuR
auto-regulatory process [73]. Short stable FGF-2 mRNAs
are present in transformed cells, whereas normal ﬁbro-
blasts contain mostly long ARE containing unstable
mRNAs [172]. The effect of alternative polyadenylation
on ARE-mediated mRNA stability was also demonstrated
with VEGF mRNA [174].
Effect of hypoxia and angiogenesis factors
on ARE-mediated pathways
Hypoxia in the tumor environment or in an inﬂammatory
tumor microenvironment triggers the expression of the
ARE-mRNA product, HIFa, which in turn induces a
range of HIF-responsive genes including those encoding
other ARE-mRNAs, notably VEGF (Fig. 1). In addition
to transcriptional induction, both VEGF and HIF
expression is modulated by ARE-mediated post-tran-
scriptional effects in response to hypoxia. HuR binds to a
U-rich region in VEGF 30UTR and mediates increased
mRNA stability [175]. A number of RNA-binding pro-
teins, e.g., HuR and PTB (polypyrimidine tract-binding
protein), bind to U-rich/AU-rich region of VEGF and HIF
30UTRs [176]. HIF1a also has a VEGF-independent role
in the regulation of glycolytic capacity in myeloid cells
contributing to the survival of macrophages and other
cells in the tumor microenvironment [25]. The loss of
Von Hippel-Lindau (VHL) tumor suppressor action leads
to increased VEGF expression at a post-transcriptional
level contributing further to hypoxia-induced angiogene-
sis in certain tumor types such as renal carcinomas [177].
This effect may be mediated by TTP down-regulation
since VHL decreases TTP expression [178]. Another
protein affected in renal cancer by VHL gene loss is the
survival factor, parathyroid hormone-related protein
(PTHrP), in which its mRNA stability is altered by HuR
[179]. As HIF-1a is constitutively overexpressed in sev-
eral cancers as a result of hypoxia, it also increases ARE-
mRNA stability of VEGF [23] in a manner that is
associated with HuR expression and cytoplasmic locali-
zation. Thus, both overexpression and cytoplasmic
localization of HuR during tumorgenesis further promote
the processes of cancer such as angiogenesis (e.g.,
VEGF) and invasion/metastasis (uPA). Additionally, loss
of TTP in cancer increases HIF1a [164], and promotes
angiogenesis-related processes.
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decay
The ARE binding proteins T cell internal antigen-1 (TIA-1)
and TIA-1 related protein (TIAR) are translational silenc-
ers for TNF-a and certain Class II ARE mRNA
translations. They bind ARE in TNF-a mRNA molecules
without affecting the mRNA stability itself. As a result,
mRNAs are diverted from the polysomes to untranslated
messenger ribonucleoproteins in a form of stress granules,
cytoplasmic domains into which mRNAs are sorted
dynamically [180, 181]. The role of TIA in inﬂammation is
observed with TIA knockdown mice which develop mild
arthritis [182]. In cancer, loss of ARE-mediated transla-
tional repression by TIA due to defective binding to the
ARE promotes COX-2 expression as observed with certain
colon cancer cell lines [183].
Removal of the ARE stretch correlates with the
increased oncogenicity of proto-oncogene fos [184]. Bcl-2
mRNA is an ARE-mRNA in which its increased stability
may lead to overproduction of the antiapoptotic BCL-2
protein likely responsible for neoplastic transformation of
follicular B cell lymphoma [185, 186]. The mRNA of the
transcription factor CHOP, which is involved in cell divi-
sion and apoptosis in response to stress, is regulated by
ARE [187]. Increased constitutive expression of an ARE-
mRNA isoform for 6-phosphofructoso-2-kinase, which is a
key enzyme in the Warbug effect of the oxygen-dependent
enhanced glycolysis in cancer cells, has been shown to be
required for tumor growth in vitro and in vivo [188]. In the
same context of enhanced glucose metabolism in cancer
cells, the stability of glucose transporter Glut1 mRNA has
been shown to be regulated by ARE and ARE binding
proteins and correlates with certain tumors including gli-
omas [189]. Increased production of hematopoietic growth
factors, e.g., GM-CSF, acting as autocrine growth factor
due to defects in ARE-mediated stability may contribute to
leukemia pathogenesis [190].
Conclusions and ﬁnal remarks
The sequence heterogeneity of ARE, the high number
ARE-genes, and the multiple signaling pathways that
change the behavior of so many RNA-binding proteins are
indicative of the high complexity and repertoire of ARE
interactome. Changes in any of these various players and
processes may disturb ARE-mediated post-transcriptional
pathways leading to speciﬁc abnormalities seen in chronic
inﬂammation and cancer. Overexpression and cytoplasmic
localization of stabilizing ARE binding proteins, notably
HuR, with commitment functional loss of RNA decay-
promoting proteins such as TTP can be associated with
chronic inﬂammation and cancer. Continued production of
pro-inﬂammatory and pro-cancer ARE-gene products can
then result from aberrations in ARE-mediated processes
that affect mRNA stability and translation (Table 3). The
ARE-gene family is close to 15% of the human transcrip-
tome, which contains functionally diverse proteins, thus
one can speculate on the involvement of many of the
deregulated ARE-mRNAs in chronic inﬂammation and any
of the cancer processes. Therapeutic interventions that aim
to control aberrant signaling pathways, both in chronic
inﬂammation and cancer, might also lead to the control of
sustained ARE-mediated post-transcriptional gene expres-
sion events. Knowledge on the interplay and redundancy of
RNA-protein interactions in inﬂammation and cancer may
result in the design of new therapeutic approaches that aim
at chronic inﬂammatory diseases and cancer, and their
linked pathology.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Halees AS, El-Badrawi R, Khabar KS (2008) ARED organism:
expansion of ARED reveals AU-rich element cluster variations
between human and mouse. Nucleic Acids Res 36:D137–D140
2. Bakheet T, Williams BR, Khabar KS (2006) ARED 3.0: the
large and diverse AU-rich transcriptome. Nucleic Acids Res
34:D111–D114
3. Yang E, Van Nimwegen E, Zavolan M, Rajewsky N, Schroeder
M, Magnasco M, Darnell JE Jr (2003) Decay rates of human
mRNAs: correlation with functional characteristics and
sequence attributes. Genome Res 13:1863–1872
4. Blackshear PJ (2002) Tristetraprolin and other CCCH tandem
zinc-ﬁnger proteins in the regulation of mRNA turnover. Bio-
chem Soc Trans 30:945–952
5. Chou CF, Mulky A, Maitra S, Lin WJ, Gherzi R, Kappes J, Chen
CY (2006) Tethering KSRP, a decay-promoting AU-rich ele-
ment-binding protein, to mRNAs elicits mRNA decay. Mol Cell
Biol 26:3695–3706
6. Schmidlin M, Lu M, Leuenberger SA, Stoecklin G, Mallaun M,
Gross B, Gherzi R, Hess D, Hemmings BA, Moroni C (2004)
The ARE-dependent mRNA-destabilizing activity of BRF1 is
regulated by protein kinase B. EMBO J 23:4760–4769
Table 3 Potential mechanisms of aberrations in ARE-mediated post-
transcriptional control in inﬂammation and cancer
Overexpression of RNA-binding stabilizing proteins
Aberrant localization of RNA-binding proteins
Chromosomal deletions and mutations of ARE regions
Promoter silencing of RNA decay promoting proteins
miRNA-mediated silencing of RNA decay promoting proteins
Differential expression of alternative ARE-deﬁcient transcripts
AU-rich elements in inﬂammation and cancer 29497. Barreau C, Paillard L, Osborne HB (2005) AU-rich elements
and associated factors: are there unifying principles? Nucleic
Acids Res 33:7138–7150
8. Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias
G (1999) Impaired on/off regulation of TNF biosynthesis in
mice lacking TNF AU- rich elements: implications for joint and
gut-associated immunopathologies. Immunity 10:387–398
9. Taylor GA, Carballo E, Lee DM, Lai WS, Thompson MJ, Patel
DD, Schenkman DI, Gilkeson GS, Broxmeyer HE, Haynes BF,
Blackshear PJ (1996) A pathogenetic role for TNF alpha in the
syndrome of cachexia, arthritis, and autoimmunity resulting
from tristetraprolin (TTP) deﬁciency. Immunity 4:445–454
10. Carballo E, Lai WS, Blackshear PJ (1998) Feedback inhibition
of macrophage tumor necrosis factor-alpha production by
tristetraprolin. Science 281:1001–1005
11. Balkwill F (2009) Tumour necrosis factor and cancer. Nat Rev
Cancer 9:361–371
12. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem
S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y
(2004) NF-kappaB functions as a tumour promoter in inﬂam-
mation-associated cancer. Nature 431:461–466
13. Popivanova BK, Kitamura K, Wu Y, Kondo T, Kagaya T,
Kaneko S, Oshima M, Fujii C, Mukaida N (2008) Blocking
TNF-alpha in mice reduces colorectal carcinogenesis associated
with chronic colitis. J Clin Invest 118:560–570
14. Egberts JH, Cloosters V, Noack A, Schniewind B, Thon L,
Klose S, Kettler B, von Forstner C, Kneitz C, Tepel J, Adam D,
Wajant H, Kalthoff H, Trauzold A (2008) Anti-tumor necrosis
factor therapy inhibits pancreatic tumor growth and metastasis.
Cancer Res 68:1443–1450
15. Kulbe H, Thompson R, Wilson JL, Robinson S, Hagemann T,
Fatah R, Gould D, Ayhan A, Balkwill F (2007) The inﬂam-
matory cytokine tumor necrosis factor-alpha generates an
autocrine tumor-promoting network in epithelial ovarian cancer
cells. Cancer Res 67:585–592
16. Liu RY, Fan C, Liu G, Olashaw NE, Zuckerman KS (2000)
Activation of p38 mitogen-activated protein kinase is required
for tumor necrosis factor-alpha -supported proliferation of leu-
kemia and lymphoma cell lines. J Biol Chem 275:21086–21093
17. Bates RC, Mercurio AM (2003) Tumor necrosis factor-alpha
stimulates the epithelial-to-mesenchymal transition of human
colonic organoids. Mol Biol Cell 14:1790–1800
18. Popivanova BK, Kostadinova FI, Furuichi K, Shamekh MM,
Kondo T, Wada T, Egashira K, Mukaida N (2009) Blockade of a
chemokine, CCL2, reduces chronic colitis-associated carcino-
genesis in mice. Cancer Res 69:7884–7892
19. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN
(1998) Cyclooxygenase regulates angiogenesis induced by colon
cancer cells. Cell 93:705–716
20. Sawaoka H, Tsuji S, Tsujii M, Gunawan ES, Sasaki Y, Kawano
S, Hori M (1999) Cyclooxygenase inhibitors suppress angio-
genesis and reduce tumor growth in vivo. Lab Invest 79:1469–
1477
21. Li G, Yang T, Yan J (2002) Cyclooxygenase-2 increased the
angiogenic and metastatic potential of tumor cells. Biochem
Biophys Res Commun 299:886–890
22. Franco S, Stefania V, Miquel S, Vincenzo A, Giuseppe S,
Egidio S, Alessandro R, Andreas S, Alberto M, Julian P, Seppo
YH, Claudio F, Silvio D (2009) VEGF-A links angiogenesis and
inﬂammation in inﬂammatory bowel disease pathogenesis.
Gastroenterology 136:585–595, e585
23. Liu LX, Lu H, Luo Y, Date T, Belanger AJ, Vincent KA, Akita
GY, Goldberg M, Cheng SH, Gregory RJ, Jiang C (2002) Sta-
bilization of vascular endothelial growth factor mRNA by
hypoxia-inducible factor 1. Biochem Biophys Res Commun
291:908–914
24. Scortegagna M, Cataisson C, Martin RJ, Hicklin DJ, Schreiber
RD, Yuspa SH, Arbeit JM (2008) HIF-1{alpha} regulates epi-
thelial inﬂammation by cell autonomous NF{kappa}B activation
and paracrine stromal remodeling. Blood 111:3343–3354
25. Cramer T, Yamanishi Y, Clausen BE, Forster I, Pawlinski R,
Mackman N, Haase VH, Jaenisch R, Corr M, Nizet V, Firestein
GS, Gerber HP, Ferrara N, Johnson RS (2003) HIF-1alpha is
essential for myeloid cell-mediated inﬂammation. Cell 112:645–
657
26. Andreasen PA, Egelund R, Petersen HH (2000) The plasmino-
gen activation system in tumor growth, invasion, and metastasis.
Cell Mol Life Sci 57:25–40
27. Shi Q, Abbruzzese JL, Huang S, Fidler IJ, Xiong Q, Xie K
(1999) Constitutive and inducible interleukin 8 expression by
hypoxia and acidosis renders human pancreatic cancer cells
more tumorigenic and metastatic. Clin Cancer Res 5:3711–3721
28. Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD,
Yano S, Bar-Eli M, Radinsky R, Pettaway CA, Dinney CP
(2000) Interleukin 8 expression regulates tumorigenicity and
metastases in androgen-independent prostate cancer. Clin
Cancer Res 6:2104–2119
29. Haghnegahdar H, Du J, Wang D, Strieter RM, Burdick MD,
Nanney LB, Cardwell N, Luan J, Shattuck-Brandt R, Richmond
A (2000) The tumorigenic and angiogenic effects of MGSA/
GRO proteins in melanoma. J Leukoc Biol 67:53–62
30. Hussain SP, He P, Subleski J, Hofseth LJ, Trivers GE, Mechanic
L, Hofseth AB, Bernard M, Schwank J, Nguyen G, Mathe E,
Djurickovic D, Haines D, Weiss J, Back T, Gruys E, Laubach
VE, Wiltrout RH, Harris CC (2008) Nitric oxide is a key
component in inﬂammation-accelerated tumorigenesis. Cancer
Res 68:7130–7136
31. Chen CY, Shyu AB (1995) AU-rich elements: characterization
and importance in mRNA degradation. Trends Biochem Sci
20:465–470
32. Lagnado CA, Brown CY, Goodall GJ (1994) AUUUA is not
sufﬁcient to promote poly(A) shortening and degradation of an
mRNA: the functional sequence within AU-rich elements may
be UUAUUUA(U/A)(U/A). Mol Cell Biol 14:7984–7995
33. Lewis T, Gueydan C, Huez G, Toulme JJ, Kruys V (1998)
Mapping of a minimal AU-rich sequence required for lipo-
polysaccharide- induced binding of a 55-kDa protein on tumor
necrosis factor-alpha mRNA. J Biol Chem 273:13781–13786
34. Zubiaga AM, Belasco JG, Greenberg ME (1995) The nonamer
UUAUUUAUU is the key AU-rich sequence motif that medi-
ates mRNA degradation. Mol Cell Biol 15:2219–2230
35. Lai WS, Carrick DM, Blackshear PJ (2005) Inﬂuence of
nonameric AU-rich tristetraprolin-binding sites on mRNA
deadenylation and turnover. J Biol Chem 280:34365–34377
36. Bakheet T, Frevel M, Williams BR, Greer W, Khabar KS (2001)
ARED: human AU-rich element-containing mRNA database
reveals an unexpectedly diverse functional repertoire of encoded
proteins. Nucleic Acids Res 29:246–254
37. Frevel MA, Bakheet T, Silva AM, Hissong JG, Khabar KS,
Williams BR (2003) p38 Mitogen-activated protein kinase-
dependent and -independent signaling of mRNA stability of AU-
rich element-containing transcripts. Mol Cell Biol 23:425–436
38. Raghavan A, Dhalla M, Bakheet T, Ogilvie RL, Vlasova IA,
Khabar KS, Williams BR, Bohjanen PR (2004) Patterns of
coordinate down-regulation of ARE-containing transcripts fol-
lowing immune cell activation. Genomics 84:1002–1013
39. Sharova LV, Sharov AA, Nedorezov T, Piao Y, Shaik N, Ko MS
(2009) Database for mRNA half-life of 19 977 genes obtained
by DNA microarray analysis of pluripotent and differentiating
mouse embryonic stem cells. DNA Res 16:45–58
40. Ray D, Kazan H, Chan ET, Castillo LP, Chaudhry S, Talukder
S, Blencowe BJ, Morris Q, Hughes TR (2009) Rapid and
2950 K. S. A. Khabarsystematic analysis of the RNA recognition speciﬁcities of
RNA-binding proteins. Nat Biotechnol 27:667–670
41. Meisner NC, Hackermuller J, Uhl V, Aszodi A, Jaritz M, Auer
M (2004) mRNA openers and closers: modulating AU-rich
element-controlled mRNA stability by a molecular switch in
mRNA secondary structure. Chembiochem 5:1432–1447
42. Hackermuller J, Meisner NC, Auer M, Jaritz M, Stadler PF
(2005) The effect of RNA secondary structures on RNA-ligand
binding and the modiﬁer RNA mechanism: a quantitative model.
Gene 345:3–12
43. Lopez de Silanes I, Zhan M, Lal A, Yang X, Gorospe M (2004)
Identiﬁcation of a target RNA motif for RNA-binding protein
HuR. Proc Natl Acad Sci USA 101:2987–2992
44. Park-Lee S, Kim S, Laird-Offringa IA (2003) Characterization
of the interaction between neuronal RNA-binding protein HuD
and AU-rich RNA. J Biol Chem 278:39801–39808
45. Brewer BY, Malicka J, Blackshear PJ, Wilson GM (2004) RNA
sequence elements required for high afﬁnity binding by the zinc-
ﬁnger domain of tristetraprolin: conformational changes coupled
to the bipartite nature of Au-rich MRNA-destabilizing motifs.
J Biol Chem 279:27870–27877
46. Worthington MT, Pelo JW, Sachedina MA, Applegate JL,
Arseneau KO, Pizarro TT (2002) RNA-binding properties of the
AU-rich element-binding recombinant Nup475/TIS11/triste-
traprolin protein. J Biol Chem 277:48558–48564
47. Mazan-Mamczarz K, Kuwano Y, Zhan M, White EJ, Martindale
JL, Lal A, Gorospe M (2009) Identiﬁcation of a signature motif
in target mRNAs of RNA-binding protein AUF1. Nucleic Acids
Res 37:204–214
48. Lopez de Silanes I, Galban S, Martindale JL, Yang X, Mazan-
Mamczarz K, Indig FE, Falco G, Zhan M, Gorospe M (2005)
Identiﬁcation and functional outcome of mRNAs associated
with RNA-binding protein TIA-1. Mol Cell Biol 25:9520–9531
49. Andersen JB, Mazan-Mamczarz K, Zhan M, Gorospe M, Hassel
BA (2009) Ribosomal protein mRNAs are primary targets of
regulation in RNase-L-induced senescence. RNA Biol 6:305–
315
50. Forte GI, Scola L, Bellavia D, Vaccarino L, Sanacore M, Sisino
G, Scazzone C, Caruso C, Barbieri R, Lio D (2009) Charac-
terization of two alternative Interleukin(IL)-10 5’UTR mRNA
sequences, induced by lipopolysaccharide (LPS) stimulation of
peripheral blood mononuclear cells. Mol Immunol 46:2161–
2166
51. Paste M, Huez G, Kruys V (2003) Deadenylation of interferon-
beta mRNA is mediated by both the AU-rich element in the 3’-
untranslated region and an instability sequence in the coding
region. Eur J Biochem 270:1590–1597
52. Prechtel AT, Chemnitz J, Schirmer S, Ehlers C, Langbein-
Detsch I, Stulke J, Dabauvalle MC, Kehlenbach RH, Hauber J
(2006) Expression of CD83 is regulated by HuR via a novel
cis-active coding region RNA element. J Biol Chem 281:10912–
10925
53. Al-Zoghaibi F, Ashour T, Al-Ahmadi W, Abulleef H, Demir-
kaya O, Khabar KS (2007) Bioinformatics and experimental
derivation of an efﬁcient hybrid 3’ untranslated region and use
in expression active linear DNA with minimum poly(A) region.
Gene 391:130–139
54. Mukherjee N, Lager PJ, Friedersdorf MB, Thompson MA,
Keene JD (2009) Coordinated posttranscriptional mRNA pop-
ulation dynamics during T-cell activation. Mol Syst Biol 5:288
55. Stoecklin G, Tenenbaum SA, Mayo T, Chittur SV, George AD,
Baroni TE, Blackshear PJ, Anderson P (2008) Genome-wide
analysis identiﬁes interleukin-10 mRNA as target of triste-
traprolin. J Biol Chem 283:11689–11699
56. Jing Q, Huang S, Guth S, Zarubin T, Motoyama A, Chen J, Di
Padova F, Lin SC, Gram H, Han J (2005) Involvement of
microRNA in AU-rich element-mediated mRNA instability.
Cell 120:623–634
57. Mayr C, Bartel DP (2009) Widespread shortening of 3’UTRs by
alternative cleavage and polyadenylation activates oncogenes in
cancer cells. Cell 138:673–684
58. Sandberg R, Neilson JR, Sarma A, Sharp PA, Burge CB (2008)
Proliferating cells express mRNAs with shortened 3’ untrans-
lated regions and fewer microRNA target sites. Science
320:1643–1647
59. Akashi M, Shaw G, Hachiya M, Elstner E, Suzuki G, Koefﬂer P
(1994) Number and location of AUUUA motifs: role in regu-
lating transiently expressed RNAs. Blood 83:3182–3187
60. Blackshear PJ, Lai WS, Kennington EA, Brewer G, Wilson GM,
Guan X, Zhou P (2003) Characteristics of the interaction of a
synthetic human tristetraprolin tandem zinc-ﬁnger peptide with
AU-rich element-containing RNA substrates. J Biol Chem
278:19947–19955
61. Vlasova IA, Tahoe NM, Fan D, Larsson O, Rattenbacher B,
Sternjohn JR, Vasdewani J, Karypis G, Reilly CS, Bitterman PB,
Bohjanen PR (2008) Conserved GU-rich elements mediate
mRNA decay by binding to CUG-binding protein 1. Mol Cell
29:263–270
62. Kruys V, Wathelet M, Poupart P, Contreras R, Fiers W, Content
J, Huez G (1987) The 3’ untranslated region of the human
interferon-beta mRNA has an inhibitory effect on translation.
Proc Natl Acad Sci USA 84:6030–6034
63. Kruys V, Marinx O, Shaw G, Deschamps J, Huez G (1989)
Translational blockade imposed by cytokine-derived UA-rich
sequences. Science 245:852–855
64. Vasudevan S, Steitz JA (2007) AU-rich-element-mediated
upregulation of translation by FXR1 and Argonaute 2. Cell
128:1105–1118
65. Cao H, Deterding LJ, Blackshear PJ (2007) Phosphorylation site
analysis of the anti-inﬂammatory and mRNA-destabilizing
protein tristetraprolin. Expert Rev Proteomics 4:711–726
66. Lai WS, Carballo E, Strum JR, Kennington EA, Phillips RS,
Blackshear PJ (1999) Evidence that tristetraprolin binds to AU-
Rich elements and promotes the deadenylation and destabiliza-
tion of tumor necrosis factor alpha mRNA. Mol Cell Biol
19:4311–4323
67. Taylor GA, Thompson MJ, Lai WS, Blackshear PJ (1996)
Mitogens stimulate the rapid nuclear to cytosolic translocation
of tristetraprolin, a potential zinc-ﬁnger transcription factor. Mol
Endocrinol 10:140–146
68. Carballo E, Lai WS, Blackshear PJ (2000) Evidence that
tristetraprolin is a physiological regulator of granulocyte-mac-
rophage colony stimulating factor messenger RNA
deadenylation and stability. Blood 95:1891–1899
69. Stoecklin G, Ming X-F, Looser R, Moroni C (2000) Somatic
mRNA turnover mutants implicate tristetraprolin in the inter-
leukin-3 mRNA degradation pathway. Mol Cell Biol 20:3753–
3763
70. Sawaoka H, Dixon DA, Oates JA, Boutaud O (2003) Triste-
traprolin binds to the 3’-Untranslated Region of cyclooxygenase-
2 mRNA. A polyadenylation variant in a cancer cell linelacks the
binding site. J Biol Chem 278:13928–13935
71. Young LE, Sanduja S, Bemis-Standoli K, Pena EA, Price RL,
Dixon DA (2009) The mRNA-binding proteins HuR and
tristetraprolin regulate cyclooxygenase 2 expression during
colon carcinogenesis. Gastroenterology 136:1669–1679
72. Essaﬁ-Benkhadir K, Onesto C, Stebe E, Moroni C, Pages G
(2007) Tristetraprolin inhibits ras-dependent tumor vasculari-
zation by inducing vascular endothelial growth factor mRNA
degradation. Mol Biol Cell 18:4648–4658
73. Al-Ahmadi W, Al-Ghamdi M, Al-Haj L, Al-Saif M, Khabar KS
(2009) Alternative polyadenylation variants of the RNA-binding
AU-rich elements in inﬂammation and cancer 2951protein, HuR: abundance, role of AU-rich elements and auto-
Regulation. Nucleic Acids Res 37:3612–3624
74. Lai WS, Parker JS, Grissom SF, Stumpo DJ, Blackshear PJ
(2006) Novel mRNA targets for tristetraprolin (ttp) identiﬁed by
global analysis of stabilized transcripts in TTP-deﬁcient ﬁbro-
blasts. Mol Cell Biol 26:9196–9208
75. Ma WJ, Cheng S, Campbell C, Wright A, Furneaux H (1996)
Cloning and characterization of HuR, a ubiquitously expressed
Elav-like protein. J Biol Chem 271:8144–8151
76. Atasoy U, Watson J, Patel D, Keene JD (1998) ELAV protein
HuA (HuR) can redistribute between nucleus and cytoplasm and
is upregulated during serum stimulation and T cell activation.
J Cell Sci 111:3145–3156
77. Levine TD, Gao F, King PH, Andrews LG, Keene JD (1993)
Hel-N1: an autoimmune RNA-binding protein with speciﬁcity
for 3’ uridylate-rich untranslated regions of growth factor
mRNAs. Mol Cell Biol 13:3494–3504
78. Keene JD (1999) Why is Hu where? Shuttling of early-response-
gene messenger RNA subsets. Proc Natl Acad Sci USA 96:5–7
79. Wang W, Furneaux H, Cheng H, Caldwell MC, Hutter D, Liu Y,
Holbrook N, Gorospe M (2000) HuR regulates p21 mRNA
stabilization by UV light. Mol Cell Biol 20:760–769
80. Lal A, Mazan-Mamczarz K, Kawai T, Yang X, Martindale JL,
Gorospe M (2004) Concurrent versus individual binding of HuR
and AUF1 to common labile target mRNAs. EMBO J 23:3092–
3102
81. Casolaro V, Fang X, Tancowny B, Fan J, Wu F, Srikantan S,
Asaki SY, De Fanis U, Huang SK, Gorospe M, Atasoy UX,
Stellato C (2008) Posttranscriptional regulation of IL-13 in T
cells: role of the RNA-binding protein HuR. J Allergy Clin
Immunol 121:853–859,e854
82. Lopez de Silanes I, Fan J, Galban CJ, Spencer RG, Becker KG,
Gorospe M (2004) Global analysis of HuR-regulated gene
expression in colon cancer systems of reducing complexity.
Gene Expr 12:49–59
83. Papadaki O, Milatos S, Grammenoudi S, Mukherjee N, Keene
JD, Kontoyiannis DL (2009) Control of thymic T cell matura-
tion, deletion and egress by the RNA-binding protein HuR.
J Immunol 182:6779–6788
84. Katsanou V, Milatos S, Yiakouvaki A, Sgantzis N, Kotsoni A,
Alexiou M, Harokopos V, Aidinis V, Hemberger M, Kontoy-
iannis DL (2009) The RNA-binding protein Elavl1/HuR is
essential for placental branching morphogenesis and embryonic
development. Mol Cell Biol 29:2762–2776
85. Ghosh M, Aguila HL, Michaud J, Ai Y, Wu MT, Hemmes A,
Ristimaki A, Guo C, Furneaux H, Hla T (2009) Essential role of
the RNA-binding protein HuR in progenitor cell survival in
mice. J Clin Invest 119:3530–3543
86. Houseley J, LaCava J, Tollervey D (2006) RNA-quality control
by the exosome. Nat Rev Mol Cell Biol 7:529–539
87. Gherzi R, Trabucchi M, Ponassi M, Ruggiero T, Corte G,
Moroni C, Chen CY, Khabar KS, Andersen JS, Briata P (2006)
The RNA-binding protein KSRP promotes decay of beta-Cate-
nin mRNA and is inactivated by PI3 K-AKT signaling. PLoS
Biol 5:e5
88. He C, Schneider R (2006) 14–3-3sigma is a p37 AUF1-binding
protein that facilitates AUF1 transport and AU-rich mRNA
decay. EMBO J 25:3823–3831
89. Sun L, Stoecklin G, Van Way S, Hinkovska-Galcheva V, Guo
RF, Anderson P, Shanley TP (2007) Tristetraprolin (TTP)-14–3-
3 complex formation protects TTP from dephosphorylation by
protein phosphatase 2a and stabilizes tumor necrosis factor-
alpha mRNA. J Biol Chem 282:3766–3777
90. Fenger-Gron M, Fillman C, Norrild B, Lykke-Andersen J (2005)
Multiple processing body factors and the ARE binding protein
TTP activate mRNA decapping. Mol Cell 20:905–915
91. Lykke-Andersen J, Wagner E (2005) Recruitment and activation
of mRNA decay enzymes by two ARE-mediated decay activa-
tion domains in the proteins TTP and BRF-1. Genes Dev
19:351–361
92. Stoecklin G, Mayo T, Anderson P (2006) ARE-mRNA degra-
dation requires the 5’–3’ decay pathway. EMBO Rep 7:72–77
93. Briata P, Forcales SV, Ponassi M, Corte G, Chen CY, Karin M,
Puri PL, Gherzi R (2005) p38-dependent phosphorylation of the
mRNA decay-promoting factor KSRP controls the stability of
select myogenic transcripts. Mol Cell 20:891–903
94. Briata P, Ilengo C, Corte G, Moroni C, Rosenfeld MG, Chen
CY, Gherzi R (2003) The Wnt/beta-catenin–[Pitx2 pathway
controls the turnover of Pitx2 and other unstable mRNAs. Mol
Cell 12:1201–1211
95. Sureban SM, Murmu N, Rodriguez P, May R, Maheshwari R,
Dieckgraefe BK, Houchen CW, Anant S (2007) Functional
antagonism between RNA-binding proteins HuR and CUGBP2
determines the fate of COX-2 mRNA translation. Gastroenter-
ology 132:1055–1065
96. Linker K, Pautz A, Fechir M, Hubrich T, Greeve J, Kleinert H
(2005) Involvement of KSRP in the post-transcriptional regu-
lation of human iNOS expression-complex interplay of KSRP
with TTP and HuR. Nucleic Acids Res 33:4813–4827
97. Wagner BJ, DeMaria CT, Sun Y, Wilson GM, Brewer G (1998)
Structure and genomic organization of the human AUF1 gene:
alternative pre-mRNA splicing generates four protein isoforms.
Genomics 48:195–202
98. Gouble A, Grazide S, Meggetto F, Mercier P, Delsol G, Morello
D (2002) A new player in oncogenesis: AUF1/hnRNPD over-
expression leads to tumorigenesis in transgenic mice. Cancer
Res 62:1489–1495
99. Lu JY, Sadri N, Schneider RJ (2006) Endotoxic shock in AUF1
knockout mice mediated by failure to degrade proinﬂammatory
cytokine mRNAs. Genes Dev 20:3174–3184
100. Laroia G, Cuesta R, Brewer G, Schneider RJ (1999) Control of
mRNA decay by heat shock-ubiquitin-proteasome pathway.
Science 284:499–502
101. Garnon J, Lachance C, Di Marco S, Hel Z, Marion D, Ruiz MC,
Newkirk MM, Khandjian EW, Radzioch D (2005) Fragile
X-related protein FXR1P regulates proinﬂammatory cytokine
tumor necrosis factor expression at the post-transcriptional level.
J Biol Chem 280:5750–5763
102. Steitz JA, Vasudevan S (2009) miRNPs: versatile regulators of
gene expression in vertebrate cells. Biochem Soc Trans 37:931–
935
103. Porta C, Larghi P, Rimoldi M, Totaro MG, Allavena P,
Mantovani A, Sica A (2009) Cellular and molecular pathways
linking inﬂammation and cancer. Immunobiology 214:761–777
104. Lin Y, Bai L, Chen W, Xu S (2010) The NF-kappaB activation
pathways, emerging molecular targets for cancer prevention and
therapy. Expert Opin Ther Targets 14:45–55
105. Hartupee J, Li X, Hamilton T (2008) Interleukin 1alpha-induced
NFkappaB activation and chemokine mRNA stabilization
diverge at IRAK1. J Biol Chem 283:15689–15693
106. Hoffmann E, Dittrich-Breiholz O, Holtmann H, Kracht M
(2002) Multiple control of interleukin-8 gene expression.
J Leukoc Biol 72:847–855
107. Gaestel M (2006) MAPKAP kinases—MKs—two’s company,
three’s a crowd. Nat Rev Mol Cell Biol 7:120–130
108. Dhillon AS, Hagan S, Rath O, Kolch W (2007) MAP kinase
signalling pathways in cancer. Oncogene 26:3279–3290
109. Vivanco I, Palaskas N, Tran C, Finn SP, Getz G, Kennedy NJ,
Jiao J, Rose J, Xie W, Loda M, Golub T, Mellinghoff IK, Davis
RJ, Wu H, Sawyers CL (2007) Identiﬁcation of the JNK sig-
naling pathway as a functional target of the tumor suppressor
PTEN. Cancer Cell 11:555–569
2952 K. S. A. Khabar110. Korhonen R, Linker K, Pautz A, Forstermann U, Moilanen E,
Kleinert H (2007) Post-transcriptional regulation of human
inducible nitric-oxide synthase expression by the Jun N-terminal
kinase. Mol Pharmacol 71:1427–1434
111. Brook M, Sully G, Clark AR, Saklatvala J (2000) Regulation of
tumour necrosis factor alpha mRNA stability by the mitogen-
activated protein kinase p38 signalling cascade. FEBS Lett
483:57–61
112. Holtmann H, Winzen R, Holland P, Eickemeier S, Hoffmann E,
Wallach D, Malinin NL, Cooper JA, Resch K, Kracht M (1999)
Induction of interleukin-8 synthesis integrates effects on tran-
scription and mRNA degradation from at least three different
cytokine- or stress-activated signal transduction pathways. Mol
Cell Biol 19:6742–6753
113. Montero L, Nagamine Y (1999) Regulation by p38 mitogen-
activated protein kinase of adenylate- and uridylate-rich ele-
ment-mediated urokinase-type plasminogen activator (uPA)
messenger RNA stability and uPA-dependent in vitro cell
invasion. Cancer Res 59:5286–5293
114. Pages G, Berra E, Milanini J, Levy AP, Pouyssegur J (2000)
Stress-activated protein kinases (JNK and p38/HOG) are
essential for vascular endothelial growth factor mRNA stability
[In Process Citation]. J Biol Chem 275:26484–26491
115. Wang SW, Pawlowski J, Wathen ST, Kinney SD, Lichenstein
HS, Manthey CL (1999) Cytokine mRNA decay is accelerated
by an inhibitor of p38-mitogen-activated protein kinase.
Inﬂamm Res 48:533–538
116. Winzen R, Kracht M, Ritter B, Wilhelm A, Chen CY, Shyu AB
MM, Gaestel M, Resch K, Holtmann H (1999) The p38 MAP
kinase pathway signals for cytokine-induced mRNA stabiliza-
tion via MAP kinase-activated protein kinase 2 and an AU-rich
region-targeted mechanism. EMBO J 18:4969–4980
117. Green J, Khabar KS, Koo BC, Williams BR, Polyak SJ (2006)
Stability of CXCL-8 and related AU-rich mRNAs in the context
of hepatitis C virus replication in vitro. J Infect Dis 193:802–811
118. Datta S, Novotny M, Li X, Tebo J, Hamilton TA (2004) Toll
IL-1 receptors differ in their ability to promote the stabilization
of adenosine and uridine-rich elements containing mRNA.
J Immunol 173:2755–2761
119. Novotny M, Datta S, Biswas R, Hamilton T (2005) Functionally
independent AU-rich sequence motifs regulate KC (CXCL1)
mRNA. J Biol Chem 280:30166–30174
120. Deleault KM, Skinner SJ, Brooks SA (2008) Tristetraprolin
regulates TNF TNF-[alpha] mRNA stability via a proteasome
dependent mechanism involving the combined action of the
ERK and p38 pathways. Mol Immunol 45:13–24
121. Ronkina N, Kotlyarov A, Dittrich-Breiholz O, Kracht M, Hitti
E, Milarski K, Askew R, Marusic S, Lin LL, Gaestel M, Telliez
JB (2007) The mitogen-activated protein kinase (MAPK)-acti-
vated protein kinases MK2 and MK3 cooperate in stimulation of
tumor necrosis factor biosynthesis and stabilization of p38
MAPK. Mol Cell Biol 27:170–181
122. Stoecklin G, Stubbs T, Kedersha N, Wax S, Rigby WF,
Blackwell TK, Anderson P (2004) MK2-induced tristetrapro-
lin:14–3-3 complexes prevent stress granule association and
ARE-mRNA decay. EMBO J 23:1313–1324
123. Hitti E, Iakovleva T, Brook M, Deppenmeier S, Gruber AD,
Radzioch D, Clark AR, Blackshear PJ, Kotlyarov A, Gaestel M
(2006) Mitogen-activated protein kinase-activated protein
kinase 2 regulates tumor necrosis factor mRNA stability and
translation mainly by altering tristetraprolin expression, stabil-
ity, and binding to adenine/uridine-rich element. Mol Cell Biol
26:2399–2407
124. Winzen R, Thakur BK, Dittrich-Breiholz O, Shah M, Redich N,
Dhamija S, Kracht M, Holtmann H (2007) Functional analysis
of KSRP interaction with the AU-rich element of interleukin-8
and identiﬁcation of inﬂammatory mRNA targets. Mol Cell Biol
27:8388–8400
125. Neininger A, Kontoyiannis D, Kotlyarov A, Winzen R, Eckert
R, Volk HD, Holtmann H, Kollias G, Gaestel M (2002) MK2
targets AU-rich elements and regulates biosynthesis of tumor
necrosis factor and interleukin-6 independently at different post-
transcriptional levels. J Biol Chem 277:3065–3068
126. Tudor C, Marchese FP, Hitti E, Aubareda A, Rawlinson L,
Gaestel M, Blackshear PJ, Clark AR, Saklatvala J, Dean JL
(2009) The p38 MAPK pathway inhibits tristetraprolin-directed
decay of interleukin-10 and pro-inﬂammatory mediator mRNAs
in murine macrophages. FEBS Lett 583:1933–1938
127. Ming XF, Stoecklin G, Lu M, Looser R, Moroni C (2001)
Parallel and independent regulation of interleukin-3 mRNA
turnover by phosphatidylinositol 3-kinase and p38 mitogen-
activated protein kinase. Mol Cell Biol 21:5778–5789
128. Lafarga V, Cuadrado A, Lopez de Silanes I, Bengoechea R,
Fernandez-Capetillo O, Nebreda AR (2009) p38 Mitogen-acti-
vated protein kinase- and HuR-dependent stabilization of
p21Cip1 mRNA mediates the G1/S checkpoint. Mol Cell Biol
29:4341–4351
129. Tran H, Maurer F, Nagamine Y (2003) Stabilization of uroki-
nase and urokinase receptor mRNAs by HuR is linked to its
cytoplasmic accumulation induced by activated mitogen-acti-
vated protein kinase-activated protein kinase 2. Mol Cell Biol
23:7177–7188
130. Dixon DA, Tolley ND, Bemis-Standoli K, Martinez ML,
Weyrich AS, Morrow JD, Prescott SM, Zimmerman GA (2006)
Expression of COX-2 in platelet-monocyte interactions occurs
via combinatorial regulation involving adhesion and cytokine
signaling. J Clin Invest 116:2727–2738
131. Clark A, Dean J, Tudor C, Saklatvala J (2009) Post-transcrip-
tional gene regulation by MAP kinases via AU-rich elements.
Front Biosci 14:847–871
132. Sandler H, Stoecklin G (2008) Control of mRNA decay by
phosphorylation of tristetraprolin. Biochem Soc Trans 36:491–
496
133. Kang S, Denley A, Vanhaesebroeck B, Vogt PK (2006) Onco-
genic transformation induced by the p110beta, -gamma, and
-delta isoforms of class I phosphoinositide 3-kinase. Proc Natl
Acad Sci USA 103:1289–1294
134. Hirsch E, Ciraolo E, Ghigo A, Costa C (2008) Taming the PI3 K
team to hold inﬂammation and cancer at bay. Pharmacol Ther
118:192–205
135. Madge LA, Pober JS (2000) A Phosphatidylinositol 3-kinase/akt
pathway, activated by tumor necrosis factor or interleukin-1,
inhibits apoptosis but does not activate NFjB in human endo-
thelial cells. J Biol Chem 275:15458–15465
136. Stoecklin G, Stoeckle P, Lu M, Muehlemann O, Moroni C (2001)
Cellular mutants deﬁne a common mRNA degradation pathway
targeting cytokine AU-rich elements. RNA 7:1578–1588
137. Yu W, Murray NR, Weems C, Chen L, Guo H, Ethridge R, Ceci
JD, Evers BM, Thompson EA, Fields AP (2003) Role of
cyclooxygenase 2 in protein kinase C beta II-mediated colon
carcinogenesis. J Biol Chem 278:11167–11174
138. Subbaramaiah K, Marmao TP, Dixon DA, Dannenberg AJ
(2003) Regulation of cyclooxygenase-2 mRNA stability by
taxanes. Evidence for involvement of p38, MAPKAPK-2 and
HuR. J Biol Chem 25:25
139. Lee HK, Jeong S (2006) Beta-catenin stabilizes cyclooxygen-
ase-2 mRNA by interacting with AU-rich elements of 3’-UTR.
Nucleic Acids Res 34:5705–5714
140. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind
JS (2005) Prostaglandin E2 promotes colon cancer cell growth
through a Gs-axin-beta-catenin signaling axis. Science
310:1504–1510
AU-rich elements in inﬂammation and cancer 2953141. Kang MJ, Ryu BK, Lee MG, Han J, Lee JH, Ha TK, Byun DS,
Chae KS, Lee BH, Chun HS, Lee KY, Kim HJ, Chi SG (2008)
NF-kappaB activates transcription of the RNA-binding factor
HuR, via PI3 K-AKT signaling, to promote gastric tumorigen-
esis. Gastroenterology 135:2030–2042, 2042 e2031–2033
142. Dormoy-Raclet V, Menard I, Clair E, Kurban G, Mazroui R, Di
Marco S, von Roretz C, Pause A, Gallouzi IE (2007) The RNA-
binding protein HuR promotes cell migration and cell invasion
by stabilizing the {beta}-actin mRNA in a U-rich-element-
dependent manner. Mol Cell Biol 27:5365–5380
143. Lopez de Silanes I, Fan J, Yang X, Zonderman AB, Potapova O,
Pizer ES, Gorospe M (2003) Role of the RNA-binding protein
HuR in colon carcinogenesis. Oncogene 22:7146–7154
144. Yoo PS, Mulkeen AL, Silva T, Schmitz J, Tai N, Uchio EM,
Chu E, Cha CH (2006) RNA-binding protein HUR regulates
VEGF expression in human colorectal cancer cells. J Surg Res
130:219–220
145. Abdelmohsen K, Srikantan S, Kuwano Y, Gorospe M (2008)
miR-519 reduces cell proliferation by lowering RNA-binding
protein HuR levels. Proc Natl Acad Sci USA 105:20297–20302
146. Al-Ahmadi W, Al-Haj L, Al-Mohanna FA, Silverman RH,
Khabar KS (2009) RNase L downmodulation of the RNA-
binding protein, HuR, and cellular growth. Oncogene 28:1782–
1791
147. Denkert C, Weichert W, Pest S, Koch I, Licht D, Kobel M,
Reles A, Sehouli J, Dietel M, Hauptmann S (2004) Overex-
pression of the embryonic-lethal abnormal vision-like protein
HuR in ovarian carcinoma is a prognostic factor and is associ-
ated with increased cyclooxygenase 2 expression. Cancer Res
64:189–195
148. Mrena J, Wiksten JP, Thiel A, Kokkola A, Pohjola L, Lundin J,
Nordling S, Ristimaki A, Haglund C (2005) Cyclooxygenase-2
is an independent prognostic factor in gastric cancer and its
expression is regulated by the messenger RNA stability factor
HuR. Clin Cancer Res 11:7362–7368
149. Heinonen M, Bono P, Narko K, Chang SH, Lundin J, Joensuu H,
Furneaux H, Hla T, Haglund C, Ristimaki A (2005) Cytoplasmic
HuR expression is a prognostic factor in invasive ductal breast
carcinoma. Cancer Res 65:2157–2161
150. Niesporek S, Kristiansen G, Thoma A, Weichert W, Noske A,
Buckendahl AC, Jung K, Stephan C, Dietel M, Denkert C (2008)
Expression of the ELAV-like protein HuR in human prostate
carcinoma is an indicator of disease relapse and linked to
COX-2 expression. Int J Oncol 32:341–347
151. Nabors LB, Gillespie GY, Harkins L, King PH (2001) HuR, a
RNA stability factor, is expressed in malignant brain tumors and
binds to adenine- and uridine-rich elements within the 3’
untranslated regions of cytokine and angiogenic factor mRNAs.
Cancer Res 61:2154–2161
152. Blaxall BC, Dwyer-Nield LD, Bauer AK, Bohlmeyer TJ,
Malkinson AM, Port JD (2000) Differential expression and
localization of the mRNA-binding proteins, AU-rich element
mRNA-binding protein (AUF1) and Hu antigen R (HuR), in
neoplastic lung tissue. Mol Carcinog 28:76–83
153. Brennan SE, Kuwano Y, Alkharouf N, Blackshear PJ, Gorospe
M, Wilson GM (2009) The mRNA-destabilizing protein triste-
traprolin is suppressed in many cancers, altering tumorigenic
phenotypes and patient prognosis. Cancer Res 69:5168–5176
154. Wang J, Zhao W, Guo Y, Zhang B, Xie Q, Xiang D, Gao J,
Wang B, Chen Z (2009) The expression of RNA-binding protein
HuR in non-small cell lung cancer correlates with vascular
endothelial growth factor-C expression and lymph node metas-
tasis. Oncology 76:420–429
155. Kanies CL, Smith JJ, Kis C, Schmidt C, Levy S, Khabar KS,
Morrow J, Deane N, Dixon DA, Beauchamp RD (2008) Onco-
genic Ras and transforming growth factor-beta synergistically
regulate AU-rich element-containing mRNAs during epithelial
to mesenchymal transition. Mol Cancer Res 6:1124–1136
156. Dixon DA, Tolley ND, King PH, Nabors LB, McIntyre TM,
Zimmerman GA, Prescott SM (2001) Altered expression of the
mRNA stability factor HuR promotes cyclooxygenase-2
expression in colon cancer cells. J Clin Invest 108:1657–1665
157. Oyesanya RA, Lee ZP, Wu J, Chen J, Song Y, Mukherjee A,
Dent P, Kordula T, Zhou H, Fang X (2008) Transcriptional and
post-transcriptional mechanisms for lysophosphatidic acid-
induced cyclooxygenase-2 expression in ovarian cancer cells.
FASEB J 22:2639–2651
158. Lim SJ, Kim HJ, Kim JY, Park K, Lee CM (2007) Expression of
HuR is associated with increased cyclooxygenase-2 expression
in uterine cervical carcinoma. Int J Gynecol Pathol 26:229–234
159. Denkert C, Koch I, von Keyserlingk N, Noske A, Niesporek S,
Dietel M, Weichert W (2006) Expression of the ELAV-like
protein HuR in human colon cancer: association with tumor
stage and cyclooxygenase-2. Mod Pathol 19:1261–1269
160. Farooq F, Balabanian S, Liu X, Holcik M, MacKenzie A (2009)
p38 Mitogen-activated protein kinase stabilizes SMN mRNA
through RNA-binding protein HuR. Hum Mol Genet 18:4035–
4045
161. Doller A, Pfeilschifter J, Eberhardt W (2008) Signalling path-
ways regulating nucleo-cytoplasmic shuttling of the mRNA-
binding protein HuR. Cell Signal 20:2165–2173
162. Al-Souhibani N, Al-Ahmadi W, Hesketh J, Blackshear P,
Khabar K (2010) The RNA-binding zinc-ﬁnger protein triste-
traprolin regulates AU-rich mRNAs involved in breast cancer-
related processes. Oncogene (in press)
163. Suswam E, Li Y, Zhang X, Gillespie GY, Li X, Shacka JJ, Lu L,
Zheng L, King PH (2008) Tristetraprolin down-regulates inter-
leukin-8 and vascular endothelial growth factor in malignant
glioma cells. Cancer Res 68:674–682
164. Kim TW, Yim S, Choi BJ, Jang Y, Lee JJ, Sohn BH, Yoo H-S,
Yeom YI, Park KC (2010) Tristetraprolin regulates the stability
of HIF-1[alpha] mRNA during prolonged hypoxia. Biochem
Biophys Res Commun 391:963–968
165. Gebeshuber CA, Zatloukal K, Martinez J (2009) miR-29a sup-
presses tristetraprolin, which is a regulator of epithelial polarity
and metastasis. EMBO Rep 10:400–405
166. Schaljo B, Kratochvill F, Gratz N, Sadzak I, Sauer I, Hammer
M, Vogl C, Strobl B, Muller M, Blackshear PJ, Poli V, Lang R,
Murray PJ, Kovarik P (2009) Tristetraprolin is required for full
anti-inﬂammatory response of murine macrophages to IL-10.
J Immunol 183:1197–1206
167. Correa I, Veny M, Esteller M, Pique JM, Yague J, Panes J, Salas
A (2009) Defective IL-10 production in severe phenotypes of
Crohn’s disease. J Leukoc Biol 85:896–903
168. Sturlan S, Oberhuber G, Beinhauer BG, Tichy B, Kappel S,
Wang J, Rogy MA (2001) Interleukin-10-deﬁcient mice and
inﬂammatory bowel disease associated cancer development.
Carcinogenesis 22:665–671
169. Mosser DM, Zhang X (2008) Interleukin-10: new perspectives
on an old cytokine. Immunol Rev 226:205–218
170. Howell WM, Rose-Zerilli MJ (2007) Cytokine gene polymor-
phisms, cancer susceptibility, and prognosis. J Nutr 137:194S–
199S
171. Ristimaki A, Narko K, Hla T (1996) Down-regulation of cyto-
kine-induced cyclo-oxygenase-2 transcript isoforms by
dexamethasone: evidence for post-transcriptional regulation.
Biochem J 318:325–331
172. Touriol C, Morillon A, Gensac MC, Prats H, Prats AC (1999)
Expression of human ﬁbroblast growth factor 2 mRNA is post-
transcriptionally controlled by a unique destabilizing element
present in the 3’-untranslated region between alternative poly-
adenylation sites. J Biol Chem 274:21402–21408
2954 K. S. A. Khabar173. Rimokh R, Berger F, Bastard C, Klein B, French M, Archim-
baud E, Rouault JP, Santa Lucia B, Duret L, Vuillaume M et al
(1994) Rearrangement of CCND1 (BCL1/PRAD1) 3’ untrans-
lated region in mantle-cell lymphomas and t(11q13)-associated
leukemias. Blood 83:3689–3696
174. Yoo PS, Mulkeen AL, Cha CH (2006) Post-transcriptional
regulation of vascular endothelial growth factor: implications
for tumor angiogenesis. World J Gastroenterol 12:4937–4942
175. Lejbkowicz F, Goldberg-Cohen I, Levy AP (2005) New hori-
zons for VEGF. Is there a role for nuclear localization? Acta
Histochem 106:405–411
176. Claffey KP, Shih SC, Mullen A, Dziennis S, Cusick JL, Abrams
KR, Lee SW, Detmar M (1998) Identiﬁcation of a human VPF/
VEGF 3’ untranslated region mediating hypoxia-induced
mRNA stability. Mol Biol Cell 9:469–481
177. Gnarra JR, Zhou S, Merrill MJ, Wagner JR, Krumm A,
Papavassiliou E, Oldﬁeld EH, Klausner RD, Linehan WM
(1996) Post-transcriptional regulation of vascular endothelial
growth factor mRNA by the product of the VHL tumor sup-
pressor gene. Proc Natl Acad Sci USA 93:10589–10594
178. Sinha S, Dutta S, Datta K, Ghosh AK, Mukhopadhyay D (2009)
Von Hippel-Lindau gene product modulates TIS11B expression
in renal cell carcinoma: impact on vascular endothelial growth
factor expression in hypoxia. J Biol Chem 284:32610–32618
179. Danilin S, Sourbier C, Thomas L, Rothhut S, Lindner V, Helwig
JJ, Jacqmin D, Lang H, Massfelder T (2009) von Hippel-Lindau
tumor suppressor gene-dependent mRNA stabilization of the
survival factor parathyroid hormone-related protein in human
renal cell carcinoma by the RNA-binding protein HuR. Carci-
nogenesis 30:387–396
180. Piecyk M, Wax S, Beck AR, Kedersha N, Gupta M, Maritim B,
Chen S, Gueydan C, Kruys V, Streuli M, Anderson P (2000)
TIA-1 is a translational silencer that selectively regulates the
expression of TNF-alpha. EMBO J 19:4154–4163
181. Gueydan C, Droogmans L, Chalon P, Huez G, Caput D, Kruys V
(1999) Identiﬁcation of TIAR as a protein binding to the
translational regulatory AU-rich element of tumor necrosis
factor alpha mRNA. J Biol Chem 274:2322–2326
182. Phillips K, Kedersha N, Shen L, Blackshear PJ, Anderson P
(2004) Arthritis suppressor genes TIA-1 and TTP dampen the
expression of tumor necrosis factor alpha, cyclooxygenase 2,
and inﬂammatory arthritis. Proc Natl Acad Sci USA 101:2011–
2016
183. Dixon DA, Balch GC, Kedersha N, Anderson P, Zimmerman
GA, Beauchamp RD, Prescott SM (2003) Regulation of cyclo-
oxygenase-2 expression by the translational silencer TIA-1.
J Exp Med 198:475–481
184. Raymond V, Atwater JA, Verma IM (1989) Removal of an
mRNA destabilizing element correlates with the increased
oncogenicity of proto-oncogene fos. Oncogene Res 5:1–12
185. Capaccioli S, Quattrone A, Schiavone N, Calastretti A, Copreni
E, Bevilacqua A, Canti G, Gong L, Morelli S, Nicolin A (1996)
A bcl-2/IgH antisense transcript deregulates bcl-2 gene expres-
sion in human follicular lymphoma t(14;18) cell lines. Oncogene
13:105–115
186. Schiavone N, Rosini P, Quattrone A, Donnini M, Lapucci A,
Citti L, Bevilacqua A, Nicolin A, Capaccioli S (2000) A con-
served AU-rich element in the 3’ untranslated region of bcl-2
mRNA is endowed with a destabilizing function that is involved
in bcl-2 down- regulation during apoptosis. FASEB J 14:174–
184
187. Ubeda M, Schmitt-Ney M, Ferrer J, Habener JF (1999) CHOP/
GADD153 and methionyl-tRNA synthetase (MetRS) genes
overlap in a conserved region that controls mRNA stability.
Biochem Biophys Res Commun 262:31–38
188. Chesney J, Mitchell R, Benigni F, Bacher M, Spiegel L,
Al-Abed Y, Han JH, Metz C, Bucala R (1999) An inducible
gene product for 6-phosphofructo-2-kinase with an AU-rich
instability element: role in tumor cell glycolysis and the War-
burg effect. Proc Natl Acad Sci USA 96:3047–3052
189. Hamilton BJ, Nichols RC, Tsukamoto H, Boado RJ, Pardridge
WM, Rigby WF (1999) hnRnp A2 and hnRnp L bind the 3’UTR
of glucose transporter 1 mRna and exist as a complex in vivo.
Biochem Biophys Res Commun 261:646–651
190. Hoyle PE, Steelman LS, McCubrey JA (1997) Autocrine
transformation of human hematopoietic cells after transfection
with an activated granulocyte/macrophage colony stimulating
factor gene. Cytokines Cell Mol Ther 3:159–168
AU-rich elements in inﬂammation and cancer 2955